A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Substances that are recognized by the immune system and induce an immune reaction.
Tumors or cancer of the COLON.
Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies.
Sialylated Lewis blood group carbohydrate antigen found in many adenocarcinomas of the digestive tract, especially pancreatic tumors.
Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis.
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.
Substances elaborated by bacteria that have antigenic activity.
Antigens on surfaces of cells, including infectious or foreign cells or viruses. They are usually protein-containing groups on cell membranes or walls and may be isolated.
A type I keratin found associated with KERATIN-7 in ductal epithelia and gastrointestinal epithelia.
A malignant epithelial tumor with a glandular organization.
Antibodies produced by a single clone of cells.
Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.
Differentiation antigens residing on mammalian leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similar reactivity with certain subpopulations of antigens of a particular lineage or differentiation stage. The subpopulations of antigens are also known by the same CD designation.
Tumors or cancer of the RECTUM.
Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.
Serological tumor marker composed of a molecular complex of cytokeratins 8, 18, and 19. It is used in the diagnosis and staging of bronchogenic carcinoma.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Substances elaborated by viruses that have antigenic activity.
Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.
Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation.
Sites on an antigen that interact with specific antibodies.
Compounds that contain the Cl(=O)(=O)(=O)O- structure. Included under this heading is perchloric acid and the salts and ester forms of perchlorate.
Conjugated protein-carbohydrate compounds including mucins, mucoid, and amyloid glycoproteins.
The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.
A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Immunoglobulins induced by antigens specific for tumors other than the normally occurring HISTOCOMPATIBILITY ANTIGENS.
Tumors or cancer of the LIVER.
A type I keratin expressed predominately in gastrointestinal epithelia, MERKEL CELLS, and the TASTE BUDS of the oral mucosa.
Serological reactions in which an antiserum against one antigen reacts with a non-identical but closely related antigen.
A subclass of lipid-linked proteins that contain a GLYCOSYLPHOSPHATIDYLINOSITOL LINKAGE which holds them to the CELL MEMBRANE.
Liquid material found in epithelial-lined closed cavities or sacs.
The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.
Glycoproteins with the electrophoretic mobility of BETA-GLOBULINS, secreted by the placental TROPHOBLASTS into the maternal bloodstream during PREGNANCY. They can be detected 18 days after OVULATION and reach 200 mg/ml at the end of pregnancy. They are associated with fetal well-being.
Partial immunoglobulin molecules resulting from selective cleavage by proteolytic enzymes or generated through PROTEIN ENGINEERING techniques.
Vaccines or candidate vaccines designed to prevent or treat cancer. Vaccines are produced using the patient's own whole tumor cells as the source of antigens, or using tumor-specific antigens, often recombinantly produced.
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)
Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
Tumors or cancer of the LUNG.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.
Antigens expressed primarily on the membranes of living cells during sequential stages of maturation and differentiation. As immunologic markers they have high organ and tissue specificity and are useful as probes in studies of normal cell development as well as neoplastic transformation.
Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.
A specific HLA-A surface antigen subtype. Members of this subtype contain alpha chains that are encoded by the HLA-A*02 allele family.
Carbohydrate antigen most commonly seen in tumors of the ovary and occasionally seen in breast, kidney, and gastrointestinal tract tumors and normal tissue. CA 125 is clearly tumor-associated but not tumor-specific.
Use of radiolabeled antibodies for diagnostic imaging of neoplasms. Antitumor antibodies are labeled with diverse radionuclides including iodine-131, iodine-123, indium-111, or technetium-99m and injected into the patient. Images are obtained by a scintillation camera.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.
Any part or derivative of any protozoan that elicits immunity; malaria (Plasmodium) and trypanosome antigens are presently the most frequently encountered.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Washing out of the peritoneal cavity. The procedure is a diagnostic as well as a therapeutic technique following abdominal trauma or inflammation.
A genus of the family POXVIRIDAE, subfamily CHORDOPOXVIRINAE, comprising bird poxviruses. The type species is FOWLPOX VIRUS. Transmission is mechanical by ARTHROPODS.
Antibodies which react with the individual structural determinants (idiotopes) on the variable region of other antibodies.
Experimental transplantation of neoplasms in laboratory animals for research purposes.
A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.
Polyomavirus antigens which cause infection and cellular transformation. The large T antigen is necessary for the initiation of viral DNA synthesis, repression of transcription of the early region and is responsible in conjunction with the middle T antigen for the transformation of primary cells. Small T antigen is necessary for the completion of the productive infection cycle.
The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.
A trisaccharide antigen expressed on glycolipids and many cell-surface glycoproteins. In the blood the antigen is found on the surface of NEUTROPHILS; EOSINOPHILS; and MONOCYTES. In addition, CD15 antigen is a stage-specific embryonic antigen.
Tumors or cancer of the STOMACH.
Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).
Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases.
Antibodies, often monoclonal, in which the two antigen-binding sites are specific for separate ANTIGENIC DETERMINANTS. They are artificial antibodies produced by chemical crosslinking, fusion of HYBRIDOMA cells, or by molecular genetic techniques. They function as the main mediators of targeted cellular cytotoxicity and have been shown to be efficient in the targeting of drugs, toxins, radiolabeled haptens, and effector cells to diseased tissue, primarily tumors.
An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed.
Molecules on the surface of B- and T-lymphocytes that recognize and combine with specific antigens.
Glycoproteins with a wide distribution on hematopoietic and non-hematopoietic cells and strongly expressed on macrophages. CD58 mediates cell adhesion by binding to CD2; (ANTIGENS, CD2); and this enhances antigen-specific T-cell activation.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.
Established cell cultures that have the potential to propagate indefinitely.
Tumors or cancer of the SIGMOID COLON.
A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Tumors or cancer of the CECUM.
Transplantation between animals of different species.
The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B.
Substances of fungal origin that have antigenic activity.
The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.
Technique involving the diffusion of antigen or antibody through a semisolid medium, usually agar or agarose gel, with the result being a precipitin reaction.
A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)
Glycoproteins found on the membrane or surface of cells.
Form of radioimmunoassay in which excess specific labeled antibody is added directly to the test antigen being measured.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
The segment of LARGE INTESTINE between the CECUM and the RECTUM. It includes the ASCENDING COLON; the TRANSVERSE COLON; the DESCENDING COLON; and the SIGMOID COLON.
Any part or derivative of a helminth that elicits an immune reaction. The most commonly seen helminth antigens are those of the schistosomes.
Presence of fluid in the PLEURAL CAVITY as a complication of malignant disease. Malignant pleural effusions often contain actual malignant cells.
A true cyst of the PANCREAS, distinguished from the much more common PANCREATIC PSEUDOCYST by possessing a lining of mucous EPITHELIUM. Pancreatic cysts are categorized as congenital, retention, neoplastic, parasitic, enterogenous, or dermoid. Congenital cysts occur more frequently as solitary cysts but may be multiple. Retention cysts are gross enlargements of PANCREATIC DUCTS secondary to ductal obstruction. (From Bockus Gastroenterology, 4th ed, p4145)
Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.
The major group of transplantation antigens in the mouse.
A group of closely-related 72-74-kDa heterogeneous-nuclear ribonucleoproteins that are involved in RNA SPLICING events.
The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrates are composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n.
The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.
Techniques used to demonstrate or measure an immune response, and to identify or measure antigens using antibodies.
Lymphocytes responsible for cell-mediated immunity. Two types have been identified - cytotoxic (T-LYMPHOCYTES, CYTOTOXIC) and helper T-lymphocytes (T-LYMPHOCYTES, HELPER-INDUCER). They are formed when lymphocytes circulate through the THYMUS GLAND and differentiate to thymocytes. When exposed to an antigen, they divide rapidly and produce large numbers of new T cells sensitized to that antigen.
The processes triggered by interactions of ANTIBODIES with their ANTIGENS.
Tumors or cancer of the human BREAST.
The type species of the genus AVIPOXVIRUS. It is the etiologic agent of FOWLPOX.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS).
A peptide hormone that lowers calcium concentration in the blood. In humans, it is released by thyroid cells and acts to decrease the formation and absorptive activity of osteoclasts. Its role in regulating plasma calcium is much greater in children and in certain diseases than in normal adults.
Complex of at least five membrane-bound polypeptides in mature T-lymphocytes that are non-covalently associated with one another and with the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL). The CD3 complex includes the gamma, delta, epsilon, zeta, and eta chains (subunits). When antigen binds to the T-cell receptor, the CD3 complex transduces the activating signals to the cytoplasm of the T-cell. The CD3 gamma and delta chains (subunits) are separate from and not related to the gamma/delta chains of the T-cell receptor (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA).
The extracellular moiety of the POLYMERIC IMMUNOGLOBULIN RECEPTOR found alone or complexed with IGA or IGM, in a variety of external secretions (tears, bile, colostrum.) Secretory component is derived by proteolytic cleavage of the receptor during transcytosis. When immunoglobulins IgA and IgM are bound to the receptor, during their transcytosis secretory component becomes covalently attached to them generating SECRETORY IMMUNOGLOBULIN A or secretory IMMUNOGLOBULIN M.
A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.
Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2.
Those proteins recognized by antibodies from serum of animals bearing tumors induced by viruses; these proteins are presumably coded for by the nucleic acids of the same viruses that caused the neoplastic transformation.
A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.
Positive test results in subjects who do not possess the attribute for which the test is conducted. The labeling of healthy persons as diseased when screening in the detection of disease. (Last, A Dictionary of Epidemiology, 2d ed)
A technique using antibodies for identifying or quantifying a substance. Usually the substance being studied serves as antigen both in antibody production and in measurement of antibody by the test substance.
Serum that contains antibodies. It is obtained from an animal that has been immunized either by ANTIGEN injection or infection with microorganisms containing the antigen.
RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.
Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.
Exfoliate neoplastic cells circulating in the blood and associated with metastasizing tumors.
Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy.
A technique that combines protein electrophoresis and double immunodiffusion. In this procedure proteins are first separated by gel electrophoresis (usually agarose), then made visible by immunodiffusion of specific antibodies. A distinct elliptical precipitin arc results for each protein detectable by the antisera.
Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION.
Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.
Elements of limited time intervals, contributing to particular results or situations.
The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes IMMUNE COMPLEX DISEASES.
Tumors or cancer of the PERITONEUM.
Univalent antigen-binding fragments composed of one entire IMMUNOGLOBULIN LIGHT CHAIN and the amino terminal end of one of the IMMUNOGLOBULIN HEAVY CHAINS from the hinge region, linked to each other by disulfide bonds. Fab contains the IMMUNOGLOBULIN VARIABLE REGIONS, which are part of the antigen-binding site, and the first IMMUNOGLOBULIN CONSTANT REGIONS. This fragment can be obtained by digestion of immunoglobulins with the proteolytic enzyme PAPAIN.
Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (ANTIGENS, CD3). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains.
A costimulatory ligand expressed by ANTIGEN-PRESENTING CELLS that binds to CTLA-4 ANTIGEN with high specificity and to CD28 ANTIGEN with low specificity. The interaction of CD80 with CD28 ANTIGEN provides a costimulatory signal to T-LYMPHOCYTES, while its interaction with CTLA-4 ANTIGEN may play a role in inducing PERIPHERAL TOLERANCE.
Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.
The production of ANTIBODIES by proliferating and differentiated B-LYMPHOCYTES under stimulation by ANTIGENS.
A species of the CORONAVIRUS genus causing hepatitis in mice. Four strains have been identified as MHV 1, MHV 2, MHV 3, and MHV 4 (also known as MHV-JHM, which is neurotropic and causes disseminated encephalomyelitis with demyelination as well as focal liver necrosis).
The sum of the weight of all the atoms in a molecule.
Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake.
A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection.
Any of numerous agile, hollow-horned RUMINANTS of the genus Capra, in the family Bovidae, closely related to the SHEEP.
Accumulation of a drug or chemical substance in various organs (including those not relevant to its pharmacologic or therapeutic action). This distribution depends on the blood flow or perfusion rate of the organ, the ability of the drug to penetrate organ membranes, tissue specificity, protein binding. The distribution is usually expressed as tissue to plasma ratios.
Commercially prepared reagent sets, with accessory devices, containing all of the major components and literature necessary to perform one or more designated diagnostic tests or procedures. They may be for laboratory or personal use.
Nuclear antigen with a role in DNA synthesis, DNA repair, and cell cycle progression. PCNA is required for the coordinated synthesis of both leading and lagging strands at the replication fork during DNA replication. PCNA expression correlates with the proliferation activity of several malignant and non-malignant cell types.
The conic organs which usually give outlet to milk from the mammary glands.
A graphic means for assessing the ability of a screening test to discriminate between healthy and diseased persons; may also be used in other studies, e.g., distinguishing stimuli responses as to a faint stimuli or nonstimuli.

Classification of human colorectal adenocarcinoma cell lines. (1/2094)

Eleven human colorectal adenocarcinoma cell lines established in this laboratory were classified into three groups based on morphological features (light and electron microscopy), modal chromosome number, and ability to synthesize carcinoembryonic antigen (CEA). Group 1 cell lines contained both dedifferentiated and differentiating cells growing in tight clusters or islands of epithelium-like cells; their modal chromosome number was about 47, and they synthesized small to moderate amounts of CEA. Group 2 cell lines were more dedifferentiated, were hyperdiploid, and synthesized small amounts of CEA. Group 3 cell lines were morphologically similar to those of Group 1 by light microscopy. They differed ultrastructurally by containing microvesicular bodies; the modal chromosome number varied from hyperdiploid to hypertriploid or they had bimodal populations of hypodiploid and hypertriploid cells, and they synthesized relatively large amounts of CEA. No correlation could be found between Broder's grade or Duke's classification of the original tumor and modal chromosome number or ability to synthesize CEA. These findings support Nowell's hypothesis that the stem line is different for each solid tumor, which makes it difficult to relate chromosomal changes to the initiation of the neoplastic state.  (+info)

Marimastat in recurrent colorectal cancer: exploratory evaluation of biological activity by measurement of carcinoembryonic antigen. (2/2094)

Marimastat is a specific inhibitor of matrix metalloproteinases that has been shown to be effective in cancer models. A pilot, escalating-dose study of oral marimastat was performed in patients with recurrent colorectal cancer, in whom evaluation of serological response was made by measurement of carcinoembryonic antigen (CEA) levels. The study assessed the safety and tolerability of 4 weeks administration of marimastat, and determined a dose range producing detectable serological effects. Patients were recruited with a serum CEA level greater than 5 ng ml(-1), and rising by more than 25% over a 4-week screening period. Patients were treated for 28 days and entered into a continuation protocol if a serological response or clinical benefit was observed. Pharmacokinetic and safety data determined that groups of patients were recruited sequentially at 25 mg and 50 mg twice daily, and, thereafter, 10 mg twice daily, 10 mg once daily, 5 mg once daily and 20 mg once daily. A biological effect (BE) was defined as a CEA value on day 28 no greater than on day 0; a partial biological effect (PBE) was defined as a rise in CEA over the 28-day treatment period of less than 25%. Of 70 patients recruited, 63 completed the 28-day treatment period, and 55 were eligible for cancer antigen analysis. Examination of the dose-effect relationships provides evidence for a causal relationship between marimastat and biological effects: the proportion of patients with BE or PBE was higher with twice daily dosing (16 out of 25, 64%) than with once daily dosing (11 out of 30, 37%) (P = 0.043, chi2 test). Furthermore, the median rates of rise of CEA fell markedly during treatment compared with the screening period for patients receiving twice daily marimastat (P<0.0001), but not for patients receiving marimastat once daily (P = 0.25). Musculoskeletal adverse events emerged as the principal drug-related toxicity of marimastat, occurring in a dose- and time-dependent fashion. It was concluded that marimastat was associated with dose-dependent biological effects in cancer patients. The occurrence of musculoskeletal side-effects define 25 mg twice daily as the upper limit of the dose range for continuous use in further studies. Therefore, a dose range of 20 mg once daily to 25 mg twice daily seems appropriate for further studies, which should aim to demonstrate the efficacy of the drug in terms of conventional clinical end points and describe the long-term tolerability of this novel agent.  (+info)

Detection of occult lymph node metastases in esophageal cancer by minimally invasive staging combined with molecular diagnostic techniques. (3/2094)

BACKGROUND AND OBJECTIVES: Lymph node metastases are the most important prognostic factor in patients with esophageal cancer. Histologic examination misses micrometastases in up to 20% of lymph nodes evaluated. In addition, non-invasive imaging modalities are not sensitive enough to detect small lymph nodes metastases. The objective of this study was to investigate the use of reverse transcriptase-polymerase chain reaction (RT-PCR) of messenger RNA (mRNA) for carcinoembryonic antigen (CEA) to increase the detection of micrometastases in lymph nodes from patients with esophageal cancer. METHODS: RT-PCR of CEA mRNA was performed in lymph nodes from patients with malignant and benign esophageal disease. Each specimen was examined histopathologically and by RT-PCR and the results were compared. RESULTS: Metastases were present in 29 of 60 (48%) lymph nodes sample by minimally invasive staging from 13 patients with esophageal cancer when examined histopathologically. RT-PCR identified nodal metastases in 46 of these 60 (77%) samples. RT-PCR detected CEA mRNA in all 29 histologically positive samples and in 17 histologically negative lymph nodes. All lymph nodes from patients with benign disease (n = 15) were negative both histopathologically and by RT-PCR. The stage of two patients was reclassified based on the RT-PCR results, which identified lymph node spread undetected histopathologically. Both of these patients developed recurrent disease after resection of the primary tumor. CONCLUSIONS: RT-PCR is more sensitive than histologic examination in the detection of lymph node metastases in esophageal cancer and can lead to diagnosis of a more advanced stage in some patients. The combination of minimally invasive surgical techniques in combination with new molecular diagnostic techniques may improve our ability to stage cancer patients.  (+info)

The role of tumour markers in predicting skeletal metastases in breast cancer patients with equivocal bone scintigraphy. (4/2094)

Bone scintigraphy (BS) is commonly performed in the staging and postoperative monitoring of breast cancer. Nevertheless, due to low specificity it often demonstrates hot spots with equivocal interpretation, which may be misleading in the management of these patients. The aim of this study was to assess the value of a serum tumour marker panel in selecting among the patients with equivocal BS those with bone metastases. Between January 1986 and December 1995, 297 breast cancer patients were followed-up after mastectomy with serial determinations of a CEA-TPA-CA15.3 tumour marker panel, BS and liver echography. The tumour marker panel was used to select patients with equivocal BS for examination of suspicious bone areas by further imaging techniques. Up to December 1995, 158 (53%) patients showed an equivocal BS and 47 patients developed bone metastases. In the 158 patients with equivocal BS, prolonged clinical and imaging follow-up over 45 months (mean; range 12-120) was used to ascertain the presence or absence of bone metastases. In these 158 patients the negative predictive value and positive predictive value of the tumour marker panel to predict bone metastases was 97% and 75% respectively. This study shows that in breast cancer patients the CEA-TPA-CA15.3 tumour marker panel has a high value in selecting those patients with bone metastases, or at high risk of developing clinically-evident bone metastases, among the large number of subjects with equivocal BS.  (+info)

Serum YKL-40 and colorectal cancer. (5/2094)

YKL-40 is a mammalian member of the chitinase protein family. Although the function of YKL-40 is unknown, the pattern of its expression suggests a function in remodelling or degradation of extracellular matrix. High serum YKL-40 has been found in patients with recurrent breast cancer and has been related to short survival. In the present study we analysed YKL-40 in preoperative sera from patients with colorectal cancer and evaluated its relation to survival. Serum YKL-40 was determined by RIA in 603 patients. Survival after operation was registered, and median follow-up time was 61 months. Three hundred and forty patients died. Sixteen per cent of the patients with Dukes' A, 26% with Dukes' B, 19% with Dukes' C and 39% with Dukes' D had high serum YKL-40 levels (adjusted for age). Analysis of serum YKL-40 as a continuous variable showed an association between increased serum YKL-40 and short survival (P < 0.0001). Patients with high preoperative serum YKL-40 concentration had significantly shorter survival than patients with normal YKL-40 (HR = 1.7; 95% CI: 1.3-2.1, P < 0.0001). Multivariate Cox analysis including serum YKL-40, serum CEA, Dukes' stage, age and gender showed that high YKL-40 was an independent prognostic variable for short survival (HR = 1.4; 95% CI: 1.1-1.8, P = 0.007). These results suggest that YKL-40 may play an important role in tumour invasion.  (+info)

Intratumoral distribution of radiolabeled antibody and radioimmunotherapy in experimental liver metastases model of nude mouse. (6/2094)

The biodistribution and intratumoral distribution of radiolabeled anticarcinoembryonic antigen (CEA) monoclonal antibody in experimental liver metastases and the therapeutic effect of 131I-labeled anti-CEA antibody on the metastases were studied. METHODS: Three weeks after an intrasplenic injection of human colon cancer cells, mice received an intravenous injection of 125I- or 111In-labeled anti-CEA antibody F33-104. The biodistribution and tumor penetration of radiolabeled antibody were examined by using quantitative autoradiography. To evaluate the therapeutic effect, 5.55, 9.25 or 11.1 MBq (150, 250 or 300 microCi) 131I-labeled F33-104 were injected into groups of mice that had micrometastases smaller than 1 mm. Control groups were injected with phosphate-buffered saline or 131I-labeled control antibody. Mice were killed 3 wk later to determine the size of liver metastases. RESULTS: 1251-labeled F33-104 showed a high accumulation in the liver metastases (percentage of injected dose per gram of metastases [%ID/g] >24%, metastasis-to-liver ratio >9.8, metastasis-to-blood ratio >2.1); however, its accumulation was heterogeneous or peripheral in the nodules more than 1 mm in diameter. When the antibody dose was increased, antibody penetration was improved, but tumor uptake of radioactivity and specificity ratios decreased. In mice with large metastases, radioactivity in the normal tissue was lower than that in mice with small metastases, resulting in higher metastasis-to-background ratios. 111In-labeled antibody showed even higher tumor uptake than 125I-labeled antibody (>51 %ID/g). Metastases formation was suppressed in a dose-dependent manner by 131I-labeled F33-104 injection (5 of 8 mice had no macroscopic tumor after an injection of 5.55 MBq (150 microCi), and all mice had no visible metastasis after an injection of 9.25 or 11.1 MBq [250 or 300 microCi]), whereas tumor progression was seen in the control groups. CONCLUSION: Liver metastases had easy accessibility to the antibody. Micrometastases of less than 0.5 mm in diameter showed homogeneous intratumoral distribution of injected antibody and were successfully treated with 131I-labeled antibody. Very high uptake and satisfactory metastasis-to-liver ratios with 111In-labeled antibody suggest that the use of a radiometal with high beta-energy, such as 90Y or 188Re, is preferable for the successful radioimmunotherapy of metastases larger than 1 mm.  (+info)

Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. (7/2094)

Neuroendocrine tumors (NET) of the thyroid gland are rare. Apart from medullary thyroid carcinoma (MTC), metastases of gastroenteropancreatic (GEP) NET may also occur. Features of six patients (five men, one female: age range, 39-67 years) with thyroid metastases from a GEP-NET are described. Thyroid metastases were bilateral in all patients and were associated with enlarged neck lymph nodes in five. In four cases, the thyroid tumor was either the first sign of the disease (n = 2) or was an isolated site of recurrence (n = 2). The tumors were well (n = 3) or poorly differentiated (n = 3). Five tumors for which the primary site could be determined corresponded to foregut-derived tumors (3 lungs, 1 thymus and 1 pancreatic NET). One tumor demonstrated calcitonin (CT) production as shown by immunohistochemistry and elevated plasma CT levels. However, the disease history and the clinical features strongly favored a metastasizing GEP-NET. No tumoral RET proto-oncogene mutation was found in this patient. The differential diagnosis between metastatic GEP-NET and MTC is crucial because prognosis, work-up, and treatment differ greatly.  (+info)

Roles of circulating carcinoembryonic antigen and calcitonin in diagnosis of medullary thyroid carcinoma: a comparative study. (8/2094)

Carcinoembryonic antigen (CEA) and calcitonin (CT) were simultaneously determined in sera and tumor tissues from 15 patients with medullary carcinoma of the thyroid (MCT). Serum CEA was increased in all but one patient, and CT did in all of them. Both levels were significantly related to the weight of excised tumor, but not to the presence of metastasis. Furthermore, a significant correlation was noted between the basal levels of CT and CEA. Both levels fell to normal after a radical operation had been performed. Tissue concentrations of CEA and CT in the MCT were more than 100 times those in hyperthyroidism, and the ratios of tissue over serum levels averaged 770 in CEA and 1000 in CT. In the calcium infusion test, CEA levels were not significantly changed in contrast with a distinct increase in CT levels. The results indicate that CEA and CT represent separate activities of the tumor cells, and that circulating CEA together with CT is a useful indicator in the diagnosis and follow-up of the disease.  (+info)

[54 Pages Report] Check for Discount on Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016 report by Global Markets Direct. Global Markets Directs, Carcinoembryonic Antigen-Related Cell Adhesion Molecule...
Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic breast cancer. The present study examined serum tumor marker levels of carcinoembryonic antigen and cancer antigen 15-3 among patients with different subtypes of metastatic breast cancer.Methods: In this cross-sectional study, we assessed metastatic breast cancer patients diagnosed between 2005 and 2012 who referred to academic Hospitals affiliated with Mashhad University of Medical Sciences. The patients were selected by systematic randomization sampling. Demographic, clinical, pathological, and therapeutic data were collected from patients hospital records. Statistical analyses were performed by Statistical Package for the Social Sciences version 16.0 software.Results: A total of 298 eligible patients enrolled in the study.
Carcinoembryonic antigen-related cell adhesion molecule 7 is a protein that in humans is encoded by the CEACAM7 gene. ENSG00000007306 GRCh38: Ensembl release 89: ENSG00000280501, ENSG00000007306 - Ensembl, May 2017 Human PubMed Reference:. Thompson J, Zimmermann W, Nollau P, Neumaier M, Weber-Arden J, Schrewe H, Craig I, Willcocks T (Jan 1995). CGM2, a member of the carcinoembryonic antigen gene family is down-regulated in colorectal carcinomas. J Biol Chem. 269 (52): 32924-31. PMID 7806520. Thompson J, Seitz M, Chastre E, Ditter M, Aldrian C, Gespach C, Zimmermann W (May 1997). Down-regulation of carcinoembryonic antigen family member 2 expression is an early event in colorectal tumorigenesis. Cancer Res. 57 (9): 1776-84. PMID 9135022. Entrez Gene: CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7. Human CEACAM7 genome location and CEACAM7 gene details page in the UCSC Genome Browser. Douard R, Wind P, Sales JP, et al. (2006). Long-term prognostic value of detection of ...
Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) also known as CD66b (Cluster of Differentiation 66b), is a member of the carcinoembryonic antigen (CEA) gene family. Its main function is cell adhesion, cell migration, and pathogen binding. CEACAM8 is expressed exclusively on granulocytes and used as granulocyte marker. Cluster of differentiation GRCh38: Ensembl release 89: ENSG00000124469 - Ensembl, May 2017 Human PubMed Reference:. Entrez Gene: CEACAM8 carcinoembryonic antigen-related cell adhesion molecule 8. Khan WN, Frängsmyr L, Teglund S, et al. (1992). Identification of three new genes and estimation of the size of the carcinoembryonic antigen family. Genomics. 14 (2): 384-90. doi:10.1016/S0888-7543(05)80230-7. PMID 1427854. Oikawa S, Inuzuka C, Kuroki M, et al. (1991). A specific heterotypic cell adhesion activity between members of carcinoembryonic antigen family, W272 and NCA, is mediated by N-domains. J. Biol. Chem. 266 (13): 7995-8001. PMID 2022629. Berling ...
TY - JOUR. T1 - Identification of a new carcinoembryonic antigen (CEA) family member in human fetal liver - Cloning and sequence determination of pregnancy- specific glycoprotein 7. AU - Khan, Wasif Noor. AU - Hammarström, Sten. PY - 1990/4/16. Y1 - 1990/4/16. N2 - The carcinoembryonic antigen gene family consists of the CEA- and the Pregnancy-Specific Glycoprotein- (PSG) subfamilies. Human fetal liver express several PSGs. Here we report cloning and sequencing of a new PSG subfamily member, PSG7. It is the fifth type of PSG found in fetal liver. PSG7 has the N-A1-A2-B2-C domain arrangement. Unlike other PSGs the N-terminal of PSG7 is unblocked. PSG7 has a cysteine in the C-terminal domain, which may allow dimerization. Variability analysis according to Wu and Kabat reveals that the region in the N-domain corresponding to complementarity determining region 3 of immunoglobulin is different between PSG subfamily members. Many members, including PSG7, contain the RGD sequence in this region. The ...
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Looking for carcinoembryonic antigen? Find out information about carcinoembryonic antigen. A glycoprotein found in tissues of the fetal gut during the first two trimesters of pregnancy and in the peripheral blood of individuals with some forms of... Explanation of carcinoembryonic antigen
TY - JOUR. T1 - Immunohistochemical detection of carcinoembryonic antigen and P-glycoprotein in small cell lung cancer at diagnosis and relapse, with special reference to the tissue expression of CEA and response to chemotherapy. AU - Ohnoshi, T.. AU - Ueoka, H.. AU - Segawa, Y.. AU - Kiura, Katsuyuki. AU - Tabata, Masahiro. AU - Shibayama, T.. AU - Maeda, T.. AU - Miyatake, M.. AU - Takigawa, N.. AU - Kimura, I.. PY - 1992. Y1 - 1992. N2 - Small cell lung cancer (SCLC) is one of the most sensitive tumors to drug therapy; however, the majority of patients eventually relapse within a few years. Emergence of drug resistance is thought to play a major role in the dismal course of this disease. However, the mechanism of drug resistance in SCLC still remains obscure. Based on the clinical observation that a significant proportion of patients with relapsing tumor show an elevated serum carcinoembryonic antigen (CEA) concentration while serum neuron-specific enolase (NSE) concentration remains normal, ...
The Development of a Radioimmuno-Assay for Carcino-Embryonic Antigen with some Applications. Clinical Evaluation of Cercino-Ernbryonic Antigen, ...
BACKGROUND: Expansions of gene families are predictive for ongoing genetic adaptation to environmental cues. We describe such an expansion of the carcinoembryonic antigen (CEA) gene family in certain bat families. Members of the CEA family in humans and mice are exploited as cellular receptors by a number of pathogens, possibly due to their function in immunity and reproduction. The CEA family is composed of CEA-related cell adhesion molecules (CEACAMs) and secreted pregnancy-specific glycoproteins (PSGs). PSGs are almost exclusively expressed by trophoblast cells at the maternal-fetal interface. The reason why PSGs exist only in a minority of mammals is still unknown. RESULTS: Analysis of the CEA gene family in bats revealed that in certain bat families, belonging to the subgroup Yangochiroptera but not the Yinpterochiroptera subgroup an expansion of the CEA gene family took place, resulting in approximately one hundred CEA family genes in some species of the Vespertilionidae. The majority of ...
The NK killing activity is regulated by activating and inhibitory NK receptors. All of the activating ligands identified so far are either viral or stress-induced proteins. The class I MHC proteins are the ligands for most of the inhibitory NK receptors. However, in the past few years, several receptors have been identified that are able to inhibit NK killing independently of class I MHC recognition. We have previously demonstrated the existence of a novel inhibitory mechanism of NK cell cytotoxicity mediated by the homophilic carcinoembryonic Ag (CEA)-related cell adhesion molecule 1 (CEACAM1) interactions. In this study, we demonstrate that CEACAM1 also interacts heterophilically with the CEA protein. Importantly, we show that these heterophilic interactions of CEA and CEACAM1 inhibit the killing by NK cells. Because CEA is expressed on a wide range of carcinomas and commonly used as tumor marker, these results represent a novel role for the CEA protein enabling the escape of tumor cells from NK
TY - JOUR. T1 - The prognostic significance of preoperative tumor marker (CEA, CA15-3) elevation in breast cancer patients. T2 - data from the Korean Breast Cancer Society Registry. AU - Nam, Sang eun. AU - Lim, Woosung. AU - Jeong, Joon. AU - Lee, Seeyoun. AU - Choi, Jungeun. AU - Park, Heung Kyu. AU - Jung, Yong Sik. AU - Jung, Seung Pil. AU - Bae, Soo Youn. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Purpose: Tumor markers such as carcinoembryonic antigen (CEA) and cancer antigen 15-3 (CA15-3) are widely used for monitoring breast cancer. However, the prognostic efficacy of preoperative elevations of CEA and CA15-3 levels in breast cancer patients remains controversial. Methods: We retrospectively analyzed the clinicopathological parameters of 149,238 patients in the Korean Breast Cancer Society Registry Database who underwent surgery between January 2000 and December 2015. Results: The patients with elevated CA15-3/CEA levels had worse overall survival (OS) than the patients with normal CA15-3/CEA ...
Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in tissue extracts from human colon tumors. The CEA family of genes is part of the immunoglobulin superfamily. In humans, the CEA family consists of 29 genes, 18 of which are normally expressed only during fetal development. Therefore, CEA is not detectable in the blood of healthy adults, but CEA expression is observed in many types of cancer ...
Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in tissue extracts from human colon tumors. The CEA family of genes is part of the immunoglobulin superfamily. In humans, the CEA family consists of 29 genes, 18 of which are normally expressed only during fetal development. Therefore, CEA is not detectable in the blood of healthy adults, but CEA expression is observed in many types of cancer ...
The latest market report published by Credence Research, Inc. Global Carcinoembryonic Antigen (CEA) Market - Growth, Share, Opportunities, Competitive Analysis, and Forecast, 2016 - 2023, the carcinoembryonic antigen (CEA) market was valued at USD 1,624.2 Mn in 2015, and is expected to reach USD 2,787.3 Mn by 2023, expanding at a CAGR of 6.4% from 2016 to 2023.. Market Insights. According to Quest Diagnostics, CEA is an oncofetal glycoprotein present in the gastrointestinal tract and body fluids of the embryo and fetus. This antigen is also present in certain adult gastrointestinal cells, including the mucosal cells of the colorectum, and small amounts are present in blood. Market experts suggest that key growth drivers assisting the growth of CEA market comprises high prevalence of cancer, mounting global geriatric population base, high demand for minimally invasive diagnostic procedures in cancer and increasing application of CEA for diagnosis at several stages of cancer. In addition, a few ...
Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis Qingcai Meng,1–3,* Si Shi,1–3,* Chen Liang,1–3,* Dingkong Liang,1–3 Wenyan Xu,1–3 Shunrong Ji,1–3 Bo Zhang,1–3 Quanxing Ni,1–3 Jin Xu,1–3 Xianjun Yu1–3 1Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, 2Department of Oncology, Shanghai Medical College, 3Pancreatic Cancer Institute, Fudan University, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%–60% of patients with pancreatic cancer. Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized.Materials and methods: The MEDLINE, EMBASE, and Web of Science databases were
Carcinoembryonic antigen (CEA) is a glycoprotein involved in...... Carcinoembryonic antigen (CEA) is a glycoprotein involved in cell adhesion. It is normally produced during fetal development, but the production of CEA stops before birth.
Carcinoembryonic Antigen Does this test have other names? CEA What is this test? This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells. CEA is called a tumor marker because it gives information about cancer in your body. This test may help your doctor find out if your cancer treatment is working or if the cancer is returning after treatment. The test can be used with cancers of the colon and rectum, lung, breast, pancreas,...
TY - JOUR. T1 - Identification of HLA-A24 epitope peptides of carcinoembryonic antigen which induce tumor-reactive cytotoxic T lymphocyte. AU - Nukaya, I.. AU - Yasumoto, M.. AU - Iwasaki, T.. AU - Ideno, M.. AU - Sette, A.. AU - Celis, E.. AU - Takesako, K.. AU - Kato, I.. PY - 1999/1/5. Y1 - 1999/1/5. N2 - Carcinoembryonic antigen (CEA), which is expressed in several cancer types, is a potential target for specific immunotherapy. HLA-A24 is the most frequent allele among Japanese and is also frequently present in Asians and Caucasians. We tested CEA-encoded HLA-A24 binding peptides for their capacity to elicit anti-tumor cytotoxic T lymphocytes (CTL) in vitro. For this purpose, we used CD8+ T lymphocytes from peripheral blood mononuclear cells (PBMC) of a healthy donor and autologous peptide-pulsed dendritic cells as antigen-presenting cells. This approach enabled us to identify 2 peptides, QYSWFVNGTF and TYACFVSNL, which were capable of eliciting CTL lines that lysed tumor cells expressing ...
Free Online Library: France - CARCINOEMBRYONIC ANTIGEN. by Mena Report; Business, international Carcinoembryonic antigen CEA (Oncology)
In the present study we describe the establishment and characteristics of a new human tumor cell line (OV-1063) positive for carcinoembryonic antigen (CEA) originating from ovarian metastatic tumor cells. Analysis of the cultured cells during their in vitro adaptation period revealed while the primary culture exhibited a low proportion of CEA-positive cells, this proportion increased with culture passages and eventually more than 90% of the cells in the established line were CEA-positive. Thus, during the period of adaptation to in vitro growth, a selection for CEA-positive cells took place but the amount of CEA secreted per each positive cell seemed to be constant. Several tumor-associated characteristics were found positive on the established OV-1063 cell line. The in vitro growing cell line exhibited an abnormal chromosome pattern with a near-trisomy karyotype for some chromosomes, colony formation in soft agar as well as positive staining with a monoclonal antibody B38.1. Culture supernatants of the
FROM JAMA Oncology. A new study challenges the practice of measuring carcinoembryonic antigen (CEA) in patients with colon cancer prior to surgery, as is currently recommended by some guidelines. Researchers found that the levels do have predictive value about risk of recurrence when tested after surgery, but they challenge its use before. Consistent with the literature, our data show that postoperative CEA is more informative than preoperative CEA, the study authors wrote. Emphasis should be placed on postoperative CEA, and in the setting of modern high-quality imaging, we question the utility of measuring preoperative CEA.. The study, which was published online in JAMA Oncology , noted that testing for CEA - a colorectal cancer tumor marker - had more value prior to the current era of imaging because it could indicate the need to widen a search for metastases.. In the era of high-quality computed tomography (CT), the utility of measuring preoperative CEA is less obvious because an ...
CEA is a tumor-associated antigen abundantly expressed on several cancer types, including those naturally refractory to chemotherapy. The selection and characterization of human anti-CEA single-chain antibody fragments (scFv) is a first step toward the construction of new anticancer monoclonal antibodies designed for optimal blood clearance and tumor penetration. The human MA39 scFv, selected for its ability to recognize a CEA epitope expressed on human colon carcinomas, was first isolated from a large semi-synthetic ETH-2 antibody phage library, panned on human purified CEA protein. Subsequently, by in vitro mutagenesis of a gene encoding for the scFv MA39, a new library was established, and new scFv antibodies with improved affinity towards the CEA cognate epitope were selected and characterized. The scFv MA39 antibody was affinity-maturated by in vitro mutagenesis and the new scFv clone, E8, was isolated, typed for CEA family member recognition and its CEACAM1, 3 and 5 shared epitope characterized
Mouse monoclonal antibody raised against full length recombinant human Carcinoembryonic Antigen (CEA). Recombinant protein corresponding to full length human Carcinoembryonic Antigen. (MAB14723) - Products - Abnova
After last weeks post on therapeutic tumor infiltrating lymphocytes (TILs), we received a bunch of questions from readers.. I dont have time to answer them all in detail individually (sorry!), but it does provide an opportunity to review the evolving landscape and address some of them within the latest article.. It seems to be a good time to take a broader look at T cell manipulation, especially as it pertains to the application of TILs, chimeric antigen receptors (CAR), and T cell receptors (TCR).. Weve certainly come along way since the historic lecture in 1991 pictured right (photo: National Institutes of Health), but theres still some way to go before the full potential of cancer immunotherapy is reached.. ...
Increased serum CEA levels have been detected in persons with primary colorectal cancer and in patients with other malignancies involving the gastrointestinal tract, breast, lung, ovarian, prostatic, liver and pancreatic cancers. Elevated serum CEA levels have also been detected in patients with nonmalignant disease, especially patients who are older or who are smokers. CEA levels are not useful in screening the general population for undetected cancers. However, CEA levels provide important information about patient prognosis, recurrence of tumors after surgical removal, and effectiveness of therapy. ...
A novel magnetic nanoparticle-based electrochemical immunoassay of carcinoembryonic antigen (CEA) was designed as a model using CEA antibody-functionalized magnetic beads [DNA/Fe3O4/ZrO2; Fe3O4 (core)/ZrO2 (shell) nano particles (ZMPs)] as immunosensing probes. To design the immunoassay, the CEA antibody and O-phenylenediamine (OPD) were initially immobilized on a chitosan/nano gold composite membrane on a glassy carbon electrode (GCE/CS-nano Au), which was used for CEA recognition. Then, horseradish peroxidase (HRP)-labeled anti-CEA antibodies (HRP-CEA Ab2) were bound to the surface of the synthesized magnetic ZMP nanoparticles as signal tag. Thus, the sandwich-type immune complex could be formed between secondary antibody (Ab2) modified DNA/ZMPs nanochains tagged by HRP and GCE/CS-nano Au. Unlike conventional nanoparticle-based electrochemical immunoassays, the recognition elements of this immunoassay included both electron mediators and enzyme labels, which obviously simplifies the electrochemical
The global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and other cancers. In base year 2015, colorectal cancer dominated the overall market in terms of revenue. The key factors responsible for growth of CEA market are increase in number of population consuming alcohol, sedentary lifestyle, and high intake of saturated fats in all age groups. Moreover, rising preference for CEA test in cancer diagnosis and management is expected to assist its market growth in the near future.. In base year 2015, North America was observed as the largest CEA market due to high public awareness related to early cancer diagnosis, rising preference for minimally invasive cancer diagnosis tests and sophisticated health care facilities for cancer management. Incessant technological developments followed by new discoveries of specific antigens and biomarkers are anticipated to ...
This study was to determine the maximum-tolerated dose (MTD) and/or the optimal biological dose (OBD) as well as the optimal schedule for intravenous (IV) and subcutaneous (SC) administrations of RO7172508 as monotherapy, with or without obinutuzumab pre-treatment, in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors who have progressed on standard of care (SOC) treatment, are intolerant to SOC, and/or are non-amenable to SOC. This study was conducted in two parts. Part I of the study consisted of an IV single participant cohort/multiple-ascending dose-escalation to evaluate the safety of RO7172508. Part II was a multiple participant cohort/multiple-ascending dose-escalation to define the MTD and/or OBD of RO7172508 administered as single agent, IV and/or SC, in participants with tumors that are expressing high as well as moderate/low-CEA. The study switched from Part I to Part II when the maximum planned dose for Part I was reached or the ...
CEA is a large glycoprotein (~200 kD) consisting of a single polypeptide chain with varying carbohydrate components. Elevated CEA levels can be detected in smokers, patients with colorectal polyps, pancreatitis, liver disease, pulmonary infectious, inflammatory bowel disease and renal failure. Clinically, CEA is used to determine tumor recurrence post-operatively following resection of colon carcinoma.
Tumor markers play an important role in the identification of human malignancies. It has been shown that the carcinoembryonic antigen (CEA, CEACAM5) is a promoter of metastasis in epithelial cancers that is widely used as a clinical marker. The aim of this study is to elucidate the network of genes that are involved in the CEA-induced liver metastasis. Previously, we have shown that CEA is accumulated in the lungs and livers of rats by interacting with their macrophages. We identified and cloned a new gene (CEAR) for the CEA-binding protein, which is located on the surface of fixed liver macrophages, Kupffer cells (Bajenova et al, 2001). It has been shown that the interaction of CEA and CEAR proteins increases the production of IL-1, IL-10, IL-6, TNF-α cytokines (Thomas et al, 2011). This interaction changes the expression of liver adhesion molecules that enhances the survival of cancer cells to the liver. We also suggested that CEA synthesis by cancer cells may influence the E-cadherin adhesion
Carcinoembryonic Antigen (CEA) / CD66 Antibody, Mouse Monoclonal Antibody [Clone SPM584 ] validated in WB, IHC, IF, FC (AH11034-7), Abgent
Carcinoembryonic Antigen (CEA) / CD66 Antibody - Without BSA and Azide, Mouse Monoclonal Antibody [Clone SPM551 ] validated in IHC-P, IF, FC (AH10385-100), Abgent
CEACAM6 (carcinoembryonic antigen related cell adhesion molecule 6), Authors: Dessen P. Published in: Atlas Genet Cytogenet Oncol Haematol.
Carcinoembryonic antigen (CEA) answers are found in the Guide to Diagnostic Tests powered by Unbound Medicine. Available for iPhone, iPad, Android, and Web.
Global carcinoembryonic antigen market value surpassed USD 1.9 billion in 2017 and is expected to witness more than 6.7% CAGR from 2018 to 2024 owing to increasing incidences for cancer disease, especially colorectal cancer.
In this study, a sandwich-type electrochemical (EC) immunosensor was proposed to detect a carcinoembryonic antigen (CEA) based on Au-graphene and [email protected] blue (MB). The Au nanoparticles (NPs)-vertical graphene (VG) electrode efficiently amplifies the response signal by immobilizing a large amount of the c
Definition Carcinoembryonic antigen (CEA) is an antigen (protein) present in very small quantities in adult tissue. A greater than normal amount may be suggestive of cancer. Normally, its values range
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of cancer cells.
Based on previous experiments in nude mice, showing that fluoresceinated monoclonal antibodies against carcinoembryonic antigen localized specifically in human carcinoma xenografts and could be detected by laser-induced fluorescence, we performed a feasibility study to determine whether this immunophotodiagnosis method could be applied in the clinic. Six patients, with known primary colorectal carcinoma, received an i.v. injection of 4.5 or 9 mg of mouse-human chimeric anti-carcinoembryonic antigen monoclonal antibody coupled with 0.10-0.28 mg of fluorescein (molar ratio 1/10 to 1/14). The monoclonal antibody was also labeled with 0.2-0.4 mCi of 125I (1 Ci = 37 GBq). Photodetection of the tumor was done ex vivo on surgically resected tissues for the six patients and in vivo by fluorescence rectosigmoidoscopy for the sixth patient. Upon laser irradiation, clearly detectable heterogeneous green fluorescence from the dye-antibody conjugate was visually observed on all six tumors; almost n
Buy CEACAM18 elisa kit, Canine Carcinoembryonic antigen-related cell adhesion molecule 18 (CEACAM18) ELISA Kit-NP_082512.1 (MBS7211769) product datasheet at MyBioSource, ELISA Kits
Ceacam12 (untagged) - Mouse carcinoembryonic antigen-related cell adhesion molecule 12 (Ceacam12), transcript variant 1, (10ug), 10 µg.
We describe a high-throughput screening system to detect interactions between leucocyte surface proteins, taking into account that these interactions are usually of very low affinity. The method involves producing the extracellular regions of leucocyte proteins with tags so that they can be bound to nanoparticles to provide an avid reagent to screen over an array of 36 similar proteins immobilized using the Proteon XPR36 with detection by surface plasmon resonance. The system was tested using established interactions that could be detected without spurious binding. The ability to detect new interactions was shown by identifying a new interaction between carcinoembryonic antigen-related cell adhesion molecule 1 and carcinoembryonic antigen-related cell adhesion molecule 8.
Build: Wed Jun 21 18:33:50 EDT 2017 (commit: 4a3b2dc). National Center for Advancing Translational Sciences (NCATS), 6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-435-0888. ...
Hypohidrosis and anhidrosis are congenital or acquired conditions which are characterized by inadequate sweating. Acquired idiopathic generalized hypohidrosis/anhidrosis (AIGA) includes idiopathic pure sudomotor failure (IPSF), which has the following distinct features: sudden onset in youth, increased serum immunoglobulin E and responds favorably to systemic corticosteroid. No clinical markers reflecting the disease severity or activity have been established. Here, we report a case of AIGA in a Japanese patient successfully treated with repeated methylprednisolone pulse therapy. In this case, serum carcinoembryonic antigen (CEA) levels increased up to 19.8 ng/mL along with aberrant CEA immunoreactivity of eccrine sweat glands. Interestingly, the serum CEA level normalized as sweating improved with repeated methylprednisolone pulse therapy. Therefore, serum CEA level may serve as a useful clinical marker of hypohidrosis or anhidrosis.
Recently, molecule-targeting and bone-modifying agents have improved the treatment outcomes of lung cancer-derived metastatic spine tumors. Therefore, the prognostic factors for such tumors were examined, and novel scoring systems for predicting the life expectancy of patients with such tumors were proposed. In 207 patients with lung cancer-derived metastatic spine tumors (surgery 49; conservative therapy 158), we retrospectively examined the factors that influenced the post-treatment survival time (age, sex, the affected site, pathology, general condition, the number of extraspinal bone metastases, the number of spinal metastases, the presence/absence of major internal organ metastasis, paralysis state, the total Tokuhashi score, the serum alkaline phosphatase level, the serum carcinoembryonic antigen level, molecule-targeting drug treatment, and bone-modifying agent treatment). Based on the results, we devised novel scoring systems for predicting the prognosis of such patients. Univariate analyses
0062]The SMI sensor was fabricated using 0.83 μM solution of CEA molecules and its sensitivity was tested using LoVo colorectal cancer cells which are known to secret a significant amount of CEA while dividing and growing [Drewinko B., Romsdahl M. M., Yang L. Y., Ahearn M. J., Trujillo J. M., Cancer Res. 1976, 36, 467]. FIG. 2A shows the response of the sensor as a function of CEA concentration in Hams F12K medium along with the sensor response as a function of the hemoglobin concentration, as well as the non-imprinted electrode response to the CEA. From the figure it can be seen that no response is obtained when placed in a solution of hemoglobin proteins or in a solution of CEA when the sensor was not imprinted. On the other hand, for the imprinted electrode the inventors observe a rapid increase in the potential for CEA concentrations below ˜165 ng/mL, followed by a more gradual increase at higher concentrations. This change in potential reflects an accumulation of the surface charge ...
Background: Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), an immunoglobulin (Ig)-related glycoprotein, serves as cellular receptor for a variety of Gram-negative bacterial pathogens associated with the human mucosa. In particular, Neisseria gonorrhoeae, N. meningitidis, Moraxella catarrhalis, and Haemophilus influenzae possess well-characterized CEACAM1-binding adhesins. CEACAM1 is typically involved in cell-cell attachment, epithelial differentiation, neovascularisation and regulation of T-cell proliferation, and is one of the few CEACAM family members with homologues in different mammalian lineages. However, it is unknown whether bacterial adhesins of human pathogens can recognize CEACAM1 orthologues from other mammals.,br /,Results: Sequence comparisons of the amino-terminal Ig-variable-like domain of CEACAM1 reveal that the highest sequence divergence between human, murine, canine and bovine orthologues is found in the β-strands comprising the bacteria-binding ...
Our previous in vitro data suggested that CEACAM1 is involved in angiogenesis. This is supported by a recent proteomic screen for cell membrane components expressed in newly formed tumor vessels and the fact that CEACAM1 expression is upregulated in synergy with other angiogenic factors in cardiac hypoxia (17, 19). To date, however, evidence for a causal implication of CEACAM1 in angiogenesis in vivo was lacking. In the present study, we report on 2 different genetic mouse models in which the angiogenic action of CEACAM1 has been investigated: in CEACAM1endo+ mice, the expression of CEACAM1-L was targeted to endothelia via the Tie2 promoter, and in Ceacam1-/- mice, the Ceacam1 gene was inactivated by targeted disruption (29). In addition, endothelial cells were transfected with cDNAs coding for WT CEACAM1-L and for CEACAM1-L mutants harboring amino acid substitutions in the cytoplasmic domain. In these experimental systems, we provide conclusive evidence that CEACAM1 is involved in angiogenesis ...
PMID: Gut. 2013 Apr 18. Epub 2013 Apr 18. PMID: 23598352. Abstract Title: Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Abstract: OBJECTIVE: Western diet is a risk factor for Crohns disease (CD). Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) is abnormally expressed in CD patients. This allows adherent-invasive Escherichia coli (AIEC) to colonise the gut mucosa and leads to inflammation. We assessed the effects of a high fat/high sugar (HF/HS) Western diet on gut microbiota composition, barrier integrity and susceptibility to infection in transgenic CEABAC10 mice expressing human CEACAMs. DESIGN: Colonic microbiota composition and susceptibility of CEABAC10 mice to AIEC LF82 bacteria infection were determined in mice fed a conventional or HF/HS diet. Barrier function and inflammatory response were assessed by studying intestinal permeability, tight junction protein and mucin expression and ...
ORF of carcinoembryonic antigen-related cell adhesion molecule 20 (CEACAM20), transcript variant 4L in pENTER vector with CMV promoter and C-terminal FLAG and His tags.
TY - JOUR. T1 - Clinical profile of a new monoclonal antibody-based immunoassay for tissue polypeptide antigen. AU - Correale, M.. AU - Arnberg, H.. AU - Blockx, P.. AU - Bombardier, E.. AU - Castelli, M.. AU - Encabo, G.. AU - Gion, M.. AU - Klapdor, R.. AU - Martin, M.. AU - Nilsson, S.. AU - Reutgen, H.. AU - Ruggeri, G.. AU - Safi, F.. AU - Stegmuller, M.. AU - Vering, A.. PY - 1994. Y1 - 1994. N2 - Our preliminary evaluation of a new monoclonal antibody-based assay for tissue polypeptide antigen (TPA) has shown it to be clinically equivalent to the polyclonal antibody-based assay for TPA. The new assay (TPA-M) employs three monoclonal antibodies to epitopes on cytokeratins 8, 18 and 19. This multicenter, multinational study included 266 patients with newly diagnosed carcinomas of the lung, breast, large bowel and urinary bladder. TPA values from the two assays were compared with three other cytokeratin markers (TPS, CYFRA 21-1 and TPA(Cyk)) and with the established reference markers for ...
There is a growing list of tumor-associated fetal substances that show diagnostic promise and may in time have immunotherapeutic and prophylactic value (1, 2). Malignancies of the digestive system have received special attention in this regard, especially since 1965, when Gold and Freedman (3) identified a tumor-specific glycoprotein antigen in human colonic carcinomas. This so-called carcinoembryonic antigen (CEA) is also present in other adenocarcinomas of entodermally derived digestive system epithelium, as well as in human fetal and embryonic gut, pancreas, and liver during the first two trimesters of pregnancy (4). The antigen is a predominantly carbohydrate material with a molecular ...
A long-range physical map of the carcinoembryonic antigen (CEA) gene family cluster, which is located on the long arm of chromosome 19, has been constructed. This was achieved by hybridization analysis of large DNA fragments separated by pulse-field gel electrophoresis and of DNA from human/rodent somatic cell hybrids, as well as the assembly of ordered sets of cosmids for this gene region into contigs. The different approaches yielded very similar results and indicate that the entire gene family is contained within a region located at position 19q13.1-q13.2 between the CYP2A and the D19S15/D19S8 markers. The physical linkage of nine genes belonging to the CEA subgroup and their location with respect to the pregnancy-specific glycoprotein (PSG) subgroup genes have been determined, and the latter are located closer to the telomere. From large groups of ordered cosmid clones, the identity of all known CEA subgroup genes has been confirmed either by hybridization using gene-specific probes or by ...
Definition of carcinoembryonic antigen. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and definitions.
Carcinoembryonic antigen (CEA) and epithelial cadherin (E-cadherin) are considered as independent tumor markers in monitoring metastatic colorectal cancer. In this study we investigated the mechanism of CEA tumorigenesis, particularly the effect of CEA production on E-cadherin adherens junction protein complexes. As a model we used CEA-producing and non-producing MIP101 colorectal carcinoma cell lines. By immunoprecipitation we discovered the novel interactions between CEA and -catenin in the CEA excreting cells. No direct interaction has been detected between E-cadherin and CEA and no downregulation of neither -catenin nor E-cadherin in the CEA overexpressing cells. In addition, the functional interactions between E-cadherin and its binding protein- -catenin as well as between cateninand catenin have been impared in the CEA-producing cell lines. β-catenin is also a key factor in the Wnt signaling pathway that has essential functions in the regulation of cell growth ...
Carcinoembryonic antigen (CEA) and epithelial cadherin (E-cadherin) are considered as independent tumor markers in monitoring metastatic colorectal cancer. In this study we investigated the mechanism of CEA tumorigenesis, particularly the effect of CEA production on E-cadherin adherens junction protein complexes. As a model we used CEA-producing and non-producing MIP101 colorectal carcinoma cell lines. By immunoprecipitation we discovered the novel interactions between CEA and -catenin in the CEA excreting cells. No direct interaction has been detected between E-cadherin and CEA and no downregulation of neither -catenin nor E-cadherin in the CEA overexpressing cells. In addition, the functional interactions between E-cadherin and its binding protein- -catenin as well as between cateninand catenin have been impared in the CEA-producing cell lines. β-catenin is also a key factor in the Wnt signaling pathway that has essential functions in the regulation of cell growth ...
Materials. Peridinin chlorophyll protein-labeled anti-HLA-DR, FITC-conjugated anti-CD80, phycoerythrin (PE)-conjugated anti-CD86, PE-conjugated anti-CD40, and FITC-labeled anti-CD8 were purchased from BD Biosciences PharMingen (Chicago, IL). FITC-conjugated anti-HLA-A2 monoclonal antibody (clone BB7.2) was from Serotec Ltd. (Oxford, United Kingdom). Anti-human CEA (CE05) was from Neomarker (Fremont, CA). Anti-HSP27 (F-4), anti-HSP40 (C-20), anti-HSP60 (H-1), anti-HSP70 (K-20), anti-Hsc70 (B6), anti-intercellular adhesion molecule-1 (C-19), anti-B7.1 (N-20), anti-B7.2 (C-19), anti-transferrin receptor (K-20), and anti-lysosome-associated membrane glycoprotein-3 were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Anti-MHC-I (HC10) was from Roswell Park Cancer Institute (Buffalo, NY). Horseradish peroxidase-coupled secondary antibodies were from Jackson ImmunoResearch (West Grove, PA). Recombinant mouse interleukin (IL)-2 and recombinant human IL-2 were commercially obtained from Sigma (St. ...
Receiver operating characteristic (ROC) curve was constructed to evaluate the diagnostic values. The results showed that AC096655.1-002 was significantly downregulated in gastric cancer tissues compared with paired adjacent non-tumorous tissues (P , 0.001). Its expression level was significantly correlated with lymph node metastasis (P , 0.001), distant metastasis (P , 0.001), tumor-node-metastasis stages (P , 0.001), and differentiation (P = 0.030). The area under the ROC curve of AC096655.1-002 was up to 0.731. For the detection of gastric cancer, the use of AC096655.1-002 showed a remarkable improvement compared with the use of serum carcinoembryonic antigen. These results indicated that lncRNA AC096655.1-002 may be a potential biomarker in the diagnosis of gastric carcinoma.. ...
Colorectal cancer is one of the deadliest malignancies with a grim prognosis and accounted for an estimated 55,000 deaths in the United States alone in 1998 (16) . A similar trend of increasing incidence and poor outcome have been reported in Japan also (17) . Among the several new treatment strategies to treat these patients, NSAIDs have drawn much attention in recent years. NSAIDs exhibited a significant antitumor effect in animal models (18 , 19) and colorectal polyps in humans (20 , 21) . Although the exact mechanism of this antitumor effect is not clear, it has been postulated that this effect could be partially attributable to the antiangiogenic effect through modulation of COX-2 activity (19) . Results from several experimental models indicate that COX-2 expression is associated with augmentation of neovascularization (11) . However, to date, it is not clear whether a similar correlation exists in the clinical setting in colorectal carcinoma patients. This is the first report showing ...
2018 - 2020 This website and its content is copyright of EFLM. All rights reserved. Any redistribution or reproduction of part or all of the contents in any form is prohibited other than the following: you may print or download to a local hard disk extracts for your personal and non-commercial use only you may copy the content to individual third parties for their personal use, but only if you acknowledge the website as the source of the material You may not, except with our express written permission, distribute or commercially exploit the content. Nor may you transmit it or store it in any other website or other form of electronic retrieval system. ...
Sensitive detection of cancer biomarkers is valuable for clinical diagnosis and treatment assessment of cancers. Herein, we report a simple smartphone-based double-channel fluorescent setup for immunoassay. Except the smartphone, the total cost of the detection device itself is about 80 $, including a laser
Review A Dictionary to Tumor Markers and The Methods of Estimation Rahul R Nair, Jerin K Johnson protein(AFP), Carcinoembryonic antigen(CEA), Pancreatic oncofetal antigen) Abstract Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in the urine, in the tumor tissue, or in other tissues. Different tumor markers are found in different types of cancer, and levels of the same tumor marker can be altered in more than one type of cancer. In addition, tumor marker levels are not altered in all people with cancer, especially if the cancer is early stage. Some tumor marker levels can also be altered in patients with noncancerous conditions. To date, researchers have identified more than a dozen substances that seem to be expressed abnormally when some types of cancer are present. Some of these substances are also found in other conditions and diseases. Scientists ...
What carcinoembryonic antigen level should trigger further investigation during colorectal cancer follow-up? A systematic review and secondary analysis of a randomised controlled trial - Health Technology Assessment (free). Source: ACP Journal Wise ($). The results suggest that (1) CEA testing should not be used alone as a triage test; (2) in year 1, testing frequency should be increased (to monthly for 3 months and then every 2 months); (3) the threshold for investigating a single test result should be raised to 10 µg/l; (4) after the second CEA test, decisions to investigate further should be made on the basis of the trend in CEA levels; (5) the optimal threshold for investigating the CEA trend falls over time; and (6) continuing smokers should not be monitored with CEA testing.. ...
TY - JOUR. T1 - Clinical Significance of Serum Assay of CYFRA21-1 in Primary Lung Cancer. AU - Horiguchi, Takahiko. AU - Tachikawa, Souichi. AU - Munekata, Eiji. AU - Takeuchi, Noriyuki. AU - Hirabuki, Kouichi. AU - Shiga, Mamoru. AU - Sugiyama, Masahiro. AU - Kondou, Rieko. AU - Miyazaki, Junichi. AU - Handa, Misuzu. PY - 1995. Y1 - 1995. N2 - A new tumor marker for primary lung cancer was used to investigate the clinical significance of the cytokeratin 19 fragment (CYFRA 21-1). The serum level was measured in 52 patients with primary lung cancer, 38 patients with other pulmonary diseases, and 22 normal volunteers. These values were compared with values of other tumor markers (CEA, SCC, and NSE). When the cut-off value was established as 3.5 ng/ml, the positivity rate of primary lung cancer was 65%, and the false positivity rate of other pulmonary diseases was 8%. The positivity rate was the highest in squamous cell carcinoma (88.9%) and for adenocarcinoma it was 61.5%. Immunohistochemical ...
The patients general condition must be studied and improved as much as possible, since the operation is one of the considerable magnitude. Unless there is evidence of acute or subacute obstruction, the patient is placed on a liquid diet for a day. Most patients receive a bowel preparation the afternoon or evening prior to surgery. Following complete evacuation of the colon with laxatives or purgative, appropriate nonabsorbable antibiotics may be given. Parenteral antibiotic coverage is given just prior to surgery. In the presence of low-lying tumors, it may be advisable to evaluate by cystoscopy whether or not the bladder or other portions of the genitourinary tract are involved. Basal carcinoembryonic antigen levels are determined before and after resection of the neoplasm. The extent of extramural spread or fixation to adjacent organs may be evaluated with endorectal ultrasound or MRI plus computed tomography (CT) imaging. ...
TY - JOUR. T1 - Identification of new epitopes from four different tumor-associated antigens. T2 - Recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity. AU - Keogh, E.. AU - Fikes, J.. AU - Southwood, S.. AU - Celis, E.. AU - Chesnut, R.. AU - Sette, A.. PY - 2001/7/15. Y1 - 2001/7/15. N2 - Forty-two wild-type and analogue peptides derived from p53, carcinoembryonic Ag, Her2/neu, and MAGE2/3 were screened for their capacity to induce CTLs, in vitro, capable of recognizing tumor target lines. All the peptides bound HLA-A*0201 and two or more additional A2 supertype alleles with an IC50 of 500 nM or less. A total of 20 of 22 wild-type and 9 of 12 single amino acid substitution analogues were found to be immunogenic in primary in vitro CTL induction assays, using normal PBMCs and GM-CSF/IL-4-induced dendritic cells. These results suggest that peripheral T cell tolerance does not prevent, in this system, induction of CTL responses against tumor-associated Ag ...
In current surgical practice, indocyanine green (ICG) is commonly used for visualization of biliary structures and to confirm adequate perfusion of tissues. Although ICG is generally not used in clinical practice techniques for colo-rectal cancer, the use of ICG creates a technological plat-form for novel fluorophores to be introduced to the operating room for various surgical fields. In comparison with ICG, tumor-specific fluorescent o-Phenanthroline could pro-vide clearer margins between normal tissue and cells overexpressing specific antigens.3 This has been demon-strated in previous studies comparing ICG fluorescence with anti-carcinoembryonic antigen (CEA) antibodies in colon cancer.3,4 Anti-CEA antibodies have also been successful at labeling metastases in patient-derived pancreatic cancer mouse models.5 However, not all colon cancers express CEA and therefore other targets are needed ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced results from two Phase I studies evaluating the novel cancer immunotherapy CEA-TCB (RO6958688; RG7802), a molecule that binds T-cells and tumour cells simultaneously. CEA-TCB was studied in patients with carcinoembryonic antigen (CEA)-positive solid tumours, including microsatellite stable (MSS) metastatic colorectal cancers (mCRC) that overexpress CEA and progressed after at least two prior chemotherapy regimens.1 The studies demonstrated encouraging anti-tumour activity of CEA-TCB as a monotherapy, which was further enhanced in combination with TECENTRIQ® (atezolizumab). In the monotherapy, out of 31 patients with mCRC treated with CEA-TCB doses of 60mg or above, 14 patients (45%) showed either partial response (n=2, 6%) or stable disease (n=12, 39%). For the combination, of 25 patients treated with doses of 5-160mg of CEA-TCB, 11 patients with MSS mCRC were treated at doses shown to induce tumour lesion inflammation (80 and 160 mg). Nine of ...
Doctors give unbiased, helpful information on indications, contra-indications, benefits, and complications: Dr. Cohen on what is the cancer marker lab test cea something: The CEA (carcinoembryonic antigen) test is a colon cancer tumor marker. As with most tumor markers, it is not used as a screening test for colon cancer (in other words, it is not used to find the cancer because of a relatively high false positive rate) but it is used to monitor the cancer once it has been diagnosed. This is particularly useful for treated colon cancer to see if the tumor reoccurs.
CD4 (T4) is a single chain transmembrane glycoprotein and belongs to immunoglobulin supergene family. In extracellular region there are 4 immunoglobulin-like domains (1 Ig-like V-type and 3 Ig-like C2-type). Transmembrane region forms 25 aa, cytoplasmic tail consists of 38 aa. Domains 1,2 and 4 are stabilized by disulfide bonds. The intracellular domain of CD4 is associated with p56Lck, a Src-like protein tyrosine kinase. It was described that CD4 segregates into specific detergent-resistant T-cell membrane microdomains ...
The biologic and clinical significance of the oncofetal antigens carcinoembryonic antigen (CEA) and alpha1-fetoprotein (AFP) are discussed. Although the current assays for these molecules are not tumor-specific, measurement of these molecules in the circulation of cancer patients is useful either for tumor diagnosis or for management of the cancer patient in the postoperative or post-chemotherapy state. An approach to increasing the specificity of the CEA radioimmunoassay is described. ...
Considerations for a carcinoembryonic antigen test include smoking, cirrhosis and other factors that can raise CEA levels in the blood of those who do not have cancer, explains Drexel University...
Etubics Corporation is a clinical stage biotechnology company focused on developing immunotherapeutics for the treatment of cancer and vaccines against infectious diseases. The Company has a pipeline of product candidates based on our proprietary, advanced generation viral vector platform, the Etubics Platform, to generate both T cell mediated and antibody responses and its complimentary manufacturing human-based cell line. The Companys lead product, ETBX-011, has completed Phase 1/2 clinical trials in metastatic colorectal cancer patients. ETBX-011 targets carcinoembryonic antigen (CEA) which is expressed in many types of cancer and we believe the product has broad clinical application. Etubics Corporation has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute, a part of the National Institutes of Health, to investigate a multi-targeted immunotherapy approach containing three tumor-associated antigens including ETBX-011. These three antigens are highly ...
Normal and malignant cells release a variety of different vesicles into their extracellular environment. The most prominent vesicles are the microvesicles (MVs, 100-1 000 nm in diameter), which are shed of the plasma membrane, and the exosomes (70-120 nm in diameter), derivates of the endosomal system. MVs have been associated with intercellular communication processes and transport numerous proteins, lipids and RNAs. As essential component of immune-escape mechanisms tumor-derived MVs suppress immune responses. Additionally, tumor-derived MVs have been found to promote metastasis, tumor-stroma interactions and angiogenesis. Since members of the carcinoembryonic antigen related cell adhesion molecule (CEACAM)-family have been associated with similar processes, we studied the distribution and function of CEACAMs in MV fractions of different human epithelial tumor cells and of human and murine endothelial cells. Here we demonstrate that in association to their cell surface phenotype, MVs released ...
Among patients who had undergone curative surgery for primary colorectal cancer, the screening methods of computed tomography and carcinoembryonic antigen each provided an improved rate of surgical treatment of cancer recurrence ...
Our literature search identified 93 studies evaluating an overall of 70 different blood markers for CRC, including long discussed ones like carcinoembryonic antigen and carbohydrate antigens, as well as newly introduced ones like proteins identified through MS analysis. A broad timeframe with first studies from 1979 (75) to 2006 (49, 73, 74, 77, 81, 89-91, 102) was covered. The majority of studies evaluated protein markers, but in recent years, an interesting number of studies also evaluated genetic and epigenetic markers.. Overall, a broad range of sensitivity and specificity was reported for the various markers. A direct comparison of results from different studies is complicated due to the diverse populations used (different age, origin, normal, or diseased controls), the diverse number of markers evaluated (single versus combined markers) and use of different cutoff points for the same marker (M2-PK and CEA). Furthermore, the majority of markers were evaluated in only one study, especially ...
Background: To analyze the expression of Metadherin (MTDH), Carcinoembryonic Antigen related Cell adhesion Molecule 1 (CEACAM1) and Hepatitis B virus ..
A soft agarose clonogenic assay is presented which has been optimized for the growth of human gastrointestinal adenocarcinomas. Samples from 15 gastric and colonic solid tumors and from 2 noncancerous stomachs (control cultures) were disaggregated by treatment with collagenase at 37° overnight. Colonies appeared 10 to 15 days after plating, with a cloning efficiency between 0 and 0.82%, which was markedly improved by a fibroblastic feeder layer. The results suggest a correlation between cloning efficiency and the degree of differentiation of the initial tumor. Histochemistry, electron microscopy, and a carcinoembryonic antigen immunofluorescence assay showed that the colonies consisted of cells with the same characteristics as those of the original tumor. This colony formation assay appears to be potentially useful for assessing the stem cell pool of gastrointestinal tumors. It will be valuable for studying their response to chemotherapeutic agents in vitro. This clonogenic assay may also ...
On our first appointment, a month ago now, Simon had been getting on and off what is referred to as right upper quadrant pain, the decision was made at that time for Simon to have a base line CT scan, this has taken a month to come through and was due today.. Some science stuff , CEA - anyone that has been through bowel cancer treatment will be aware that there are certain blood tests you can have done that can measure carcinoembryonic antigens (CEA) in the blood. These are usually proteins that are produced by certain types cancers. Very scientific but for us we just concentrate on a number, under 5 is normal. Prior to Simons initial surgery in 2016 his was 11, and since then it has consistently been about 1.5-1.75, even prior to the surgery in Basingstoke, now you have the detail lets get to this weeks appointment.. Everything was going pretty well, we were happy, Doctor was happy and we were going through our usual checklist of question and answers, How have you been, what side effects ...
CEA (carcinoembryonic antigen) has an identity with an antigen of the mucous colic embryo, from which it takes its name, and is associated with colorectal
Thompson, John A.; Mössinger, S.; Reichhardt, V.; Engels, U.; Beauchemin, N.; Komoss, F.; Kleist, Sabine von und Zimmermann, Wolfgang (9. September 1993): A Polymerase-chain-reaction Assay for the Specific Identification of Transcripts Encoded by Individual Carcinoembryonic Antigen (CEA)-gene-family Members. In: International Journal of Cancer, Vol. 55, Nr. 2: S. 311-319 [PDF, 1MB] ...
Antibodies, Antigen, Carcinoembryonic Antigen, Chorionic Gonadotropin, Gonadotropin, Hormone, Human, Human Chorionic Gonadotropin, Immobilization, Immobilized Proteins, Immunoglobulin, Immunoglobulin G, Ionic Strength, Isoelectric Points, Magnetic, Microbeads, Nanoparticles, Orientation, Peroxidase, PH
CKs are expressed at high levels in epithelial cells, and expression is usually maintained or even increased after oncogenic transformation (34) . CKs can be detected in serum from cancer patients and are widely used serum tumor markers (1 , 2) . The mechanisms of release of soluble CKs into the extracellular compartment have been unclear. It was shown recently that apoptosis leads to the release of soluble CK fragments from tumor cells, suggesting that the widely used CK tumor markers tissue polypeptide antigen, tissue-polypeptide-specific antigen, and CYFRA 21-1 may reflect tumor apoptosis (14, 15, 16) . The results of the present study confirmed previous findings of release of soluble CK18 to the extracellular compartment during apoptosis (Fig. 3) ⇓ , but also showed that large amounts of soluble CK18 were released from cells induced to undergo necrosis (Fig. 2) ⇓ . Release of CK18 is therefore a marker of epithelial cell death and not a specific marker of apoptosis.. The in vitro data ...
Current disease and contamination sensors require expensive readout equipment or trained personnel. Yuehe Lin, Yong Tang and colleagues propose a new detection system based on pressure changes. For example, when a disease biomarker is present, it causes a chain reaction in the device that results in oxygen being released and pressure building. The pressure changes are measured by a portable barometer, and smartphone software provides an easy readout of the results.. To show the versatility of the pressure sensor, the team tested a variety of applications. Prototypes could detect carcinoembryonic antigen, a protein present in high levels in patients with colon or rectal cancer; ractopamine, which is an animal-feed additive banned in many countries; and thrombin, a cardiovascular disease marker. In addition, a mercury-ion sensor was developed for environmental pollution monitoring. The researchers say that because the results are immediately available with a smartphone, the method could enable ...
Complete information for CEACAMP5 gene (Pseudogene), Carcinoembryonic Antigen Related Cell Adhesion Molecule Pseudogene 5, including: function, proteins, disorders, pathways, orthologs, and expression. GeneCards - The Human Gene Compendium
Before Dame Partridges most recent study, Ambrosia conducted their own trial with 70 patients, with the strict criteria that they must all be over 35-years-old.. After being given plasma from individuals that were between 16 and 25 years of age, scientists noticed that there was a major difference in the biomarkers for diseases. For instance, those involved in the trial found that their cholesterol levels dropped by 10 percent, while carcinoembryonic antigens were lowered by 20 percent.. One of the patients who was involved in the Ambrosia trial was 55 years of age and was suffering from early-onset Alzheimers, and after a single transfusion of young blood found that they were already experiencing positive results. Ambrosia believes that with enough work, it may even be possible that elderly patients will only need just two injections each year to help them with health-related issues.. With so many positive results stemming from transfusions of young blood into older patients, the dream of ...
Exposure of APL as well as non-APL samples to any concentration of As2O3 did not affect the expression of beta2 integrins (CD11a and CD11b), CD45 isoforms (RA, RB and R0), CD44/H-CAM, CD33 and the CEA-related antigen family members CD66ade and CD66b, thus ...
Compare P antigen family, member 4 (prostate associated) ELISA Kits from leading suppliers on Biocompare. View specifications, prices, citations, reviews, and more.
Fletcher RH (1986). "Carcinoembryonic antigen". Ann. Intern. Med. 104 (1): 66-73. doi:10.7326/0003-4819-104-1-66. PMID 3510056 ... the sensitivity and specificity change between different sub-groups of patients may be found with the carcinoembryonic antigen ...
... the nonspecific cross-reacting antigen of carcinoembryonic antigen". Cancer Res. 57 (24): 5460-4. PMID 9407950. Kawaharata H, ... p95, or NCA-90, is related to carcinoembryonic antigens, which have been found to reduce drug toxicity by Kawaharata et al. NCI ... Hinoda Y, Itoh F, Endo T, Oikawa S, Nakazato H, Imai K (July 1997). "Decreased sensitivity of carcinoembryonic antigen cDNA- ...
Carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) also known as CD66e (Cluster of Differentiation 66e), is a ... 1987). "Carcinoembryonic antigen family: expression in a mouse L-cell transfectant and characterization of a partial cDNA in ... Boehm MK, Perkins SJ (2000). "Structural models for carcinoembryonic antigen and its complex with the single-chain Fv antibody ... 2001). "Heterogeneous RNA-binding protein M4 is a receptor for carcinoembryonic antigen in Kupffer cells". J. Biol. Chem. 276 ( ...
Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) also known as CD66b (Cluster of Differentiation 66b), is a ... 2002). "Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes ... 1992). "Identification of three new genes and estimation of the size of the carcinoembryonic antigen family". Genomics. 14 (2 ... 1991). "A specific heterotypic cell adhesion activity between members of carcinoembryonic antigen family, W272 and NCA, is ...
Carcinoembryonic antigen-related cell adhesion molecule 7 is a protein that in humans is encoded by the CEACAM7 gene. ... "Entrez Gene: CEACAM7 carcinoembryonic antigen-related cell adhesion molecule 7". Human CEACAM7 genome location and CEACAM7 gene ... 2000). "Carcinoembryonic antigen family members CEACAM6 and CEACAM7 are differentially expressed in normal tissues and ... 1989). "Analysis of the size of the carcinoembryonic antigen (CEA) gene family: isolation and sequencing of N-terminal domain ...
better source needed] Sajid KM, Chaouachi K, Mahmood R (2008). "Hookah smoking and cancer: carcinoembryonic antigen (CEA) ... Carcinoembryonic antigen (CEA) is a marker found in several forms of cancer. Levels in exclusive hookah smokers were lower ...
... and a member of the carcinoembryonic antigen (CEA) gene family. This gene encodes a member of the carcinoembryonic antigen (CEA ... "Immunochemical analysis of carcinoembryonic antigen (CEA)-related antigens differentially localized in intracellular granules ... Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) (CEACAM1) also known as CD66a (Cluster of ... Carcinoembryonic antigen Cluster of differentiation GRCh38: Ensembl release 89: ENSG00000079385 - Ensembl, May 2017 GRCm38: ...
"Immunologic characterization and molecular profile of carcinoembryonic antigen detected by monoclonal antibodies". J Immunol. ... He is well known for the discovery of a melanoma-related antigen (later, it is called, Chondroitin Sulfate Proteoglycan-4 ( ... Imai K, Ng AK, Ferrone S (1981). "Characterization of monoclonal antibodies to human melanoma-associated antigens". J Natl ...
These genes belong to a specific gene family; they are a subgroup of the carcinoembryonic antigen (CEA) family of genes. CEAs ... Khan WN, Hammarström S (1989). "Carcinoembryonic antigen gene family: molecular cloning of cDNA for a PS beta G/FL-NCA ... Khan WN, Osterman A, Hammarström S (May 1989). "Molecular cloning and expression of cDNA for a carcinoembryonic antigen-related ... Zoubir F, Khan WN, Hammarström S (May 1990). "Carcinoembryonic antigen gene family members in submandibular salivary gland: ...
... is a member of the carcinoembryonic antigen (CEA) gene family.. This gene encodes a member of the family of carcinoembryonic ... Carcinoembryonic antigen-related cell adhesion molecule 3 (CEACAM3) also known as CD66d (Cluster of Differentiation 66d), ... 1989). "Analysis of the size of the carcinoembryonic antigen (CEA) gene family: isolation and sequencing of N-terminal domain ... 1992). "Identification of three new genes and estimation of the size of the carcinoembryonic antigen family". Genomics. 14 (2 ...
Sajid, Khan; Chaouachi, Kamal; Mahmood, Rubaida (May 24, 2008). "Hookah smoking and cancer: carcinoembryonic antigen (CEA) ...
Speers WC, Picaso LG, Silverberg SG (1983). "Immunohistochemical localization of carcinoembryonic antigen in microglandular ...
"Full text , Hookah smoking and cancer: carcinoembryonic antigen (CEA) levels in exclusive/ever hookah smokers". Harm Reduction ...
... carcinoembryonic antigen) and AFP (alpha fetoprotein). The genes for these tumor markers may be used as promoter genes for ... "Exposed proliferation antigen 210 (XPA-210) in renal cell carcinoma (RCC) and oncocytoma: clinical utility and biological ... cytosolic thymidine kinase as compared to proliferating cell nuclear antigen in patients with colorectal carcinoma". Anticancer ... immunohistochemical detection of cytosolic thymidine kinase and proliferating cell nuclear antigen in breast cancer". Cancer ...
Prognostic value of carcinoembryonic antigen, CA 19-9 and CA 72-4 in gastric carcinoma. „Tumour Biol". 22 (5). s. 318-322. DOI ... Carcinoembryonic antigen in gastric cancer patients. „Oncology". 44 (4), s. 240-244, 1987. PMID: 3614814. ... Correlation of preoperative carcinoembryonic antigen levels and prognosis of gastric cancer patients. „Cancer". 73 (11), s. ...
... a putative intercellular adhesion molecule closely related to carcinoembryonic antigen". J. Exp. Med. 171 (6): 2147-52. doi: ... Human CD Antigen Chart (eBioscience) Mouse CD Antigen Chart (eBioscience) Human PECAM1 genome location and PECAM1 gene details ... Malignant endothelial cells also commonly retain the antigen, so that CD31 immunohistochemistry can also be used to demonstrate ...
"Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by ... Arcitumomab recognizes carcinoembryonic antigen (CEA), an antigen over-expressed in 95% of colorectal cancers. Consequently, ... anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics". Cancer Research. 55 (23 ... Cells in Colorectal Cancer Patients by Nested Reverse Transcription-Polymerase Chain Reaction for Carcinoembryonic Antigen ...
Carcinoembryonic Antigen(CEA) at MedicineNet Basuyau JP, Mallet E, Leroy M, Brunelle P (October 2004). "Reference intervals for ... June 2008). "Reference intervals for carcinoembryonic antigen (CEA), CA125, MUC1, Alfa-foeto-protein (AFP), neuron-specific ...
A second marker, carcinoembryonic antigen (CEA), also produced by medullary thyroid carcinoma, is released into the blood and ... The prognostic value of measuring calcitonin and carcinoembryonic antigen (CEA) concentrations in the blood was studied in 65 ... "Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma ... "Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma ...
"Prognostic Impact of Serum Calcitonin and Carcinoembryonic Antigen Doubling-Times in Patients with Medullary Thyroid Carcinoma ...
Zoubir F, Khan WN, Hammarström S (May 1990). "Carcinoembryonic antigen gene family members in submandibular salivary gland: ... and the carcinoembryonic antigen (CEA)-related proteins are members of the same multigene family". Biochemical and Biophysical ... "Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and ...
Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) (CEACAM6) also known as CD66c ( ... 1988). "Primary structure of nonspecific crossreacting antigen (NCA), a member of carcinoembryonic antigen (CEA) gene family, ... CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen)". Oikawa S, Inuzuka C, ... 2002). "Carcinoembryonic antigen-related cell adhesion molecule 1 expression and signaling in human, mouse, and rat leukocytes ...
Zoubir F, Khan WN, Hammarström S (1990). "Carcinoembryonic antigen gene family members in submandibular salivary gland: ... homology with human carcinoembryonic antigen and related proteins". Gene. 71 (2): 439-49. doi:10.1016/0378-1119(88)90061-3. ...
"Identification of Sp2 as a transcriptional repressor of carcinoembryonic antigen-related cell adhesion molecule 1 in ...
Colorectal cancer is one of the most studied areas, with 111In or 99mTc labelled epitopes of the carcinoembryonic antigen. The ... antibody capromab pendetide reacts with prostate membrane specific antigen (PMSA) and can be labelled with Indium-111. Indium- ...
... the intraepithelial lymphocytic infiltration characteristic of celiac sprue and stains positive for carcinoembryonic antigen ( ...
1989). "Analysis of the size of the carcinoembryonic antigen (CEA) gene family: isolation and sequencing of N-terminal domain ... a subgroup of the carcinoembryonic antigen gene family, in fetal liver". Biochem. Biophys. Res. Commun. 163 (3): 1197-209. doi: ...
The utility of CEA (Carcinoembryonic antigen) and CA19-9 as colorectal carcinoma (CRC) markers is limited and development of ... Ideo H, Seko A, Yamashita K (2005). "Galectin-4 binds to sulfated glycosphingolipids and carcinoembryonic antigen in patches on ... Recommended name:Galectin-4, Short name: Gal-4 Alternative name(s): Antigen NY-CO-27 L-36 lactose-binding protein, Short name: ... raft Gal-4 participates in apical trafficking Gal-4 has bactericidal activity against bacteria expressing blood group antigen ...
I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by ... Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T (Jan 1989). "Ki-1 (CD30) antigen is released by ... CD30+Antigens at the US National Library of Medicine Medical Subject Headings (MeSH) ... results from cDNA cloning and sequence comparison of the CD30 antigen from different sources". Molecular Immunology. 31 (17): ...
Serum levels of carcinoembryonic antigen (CEA) and CA19-9 are often elevated, but are not sensitive or specific enough to be ... Studies of the performance of serum markers for cholangiocarcinoma (such as carcinoembryonic antigen and CA19-9) in patients ... carcinoembryonic antigen, and mucins may aid in diagnosis.[45] Most tumors (,90%) are adenocarcinomas.[46] ...
Macrophage-1 antigen (CD11b+CD18). *VLA-4 (CD49d+CD29). *Glycoprotein IIb/IIIa (ITGA2B+ITGB3) ...
"Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin". Molecular and ...
"Carcinoembryonic antigen: evidence for multiple antigenic determinants and isoantigens". Proceedings of the National Academy of ...
Carcinoembryonic antigen blood level measurements follow the same timing, but are only advised for people with T2 or greater ... It has been suggested that the presence of antibodies to Streptococcus bovis/gallolyticus antigens or the antigens themselves ...
In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. The following is a ... Carcinoembryonic Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) CEA at Lab Tests Online CEA: ... Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally ... Ballesta, AM; Molina, R; Filella, X; Jo, J; Giménez, N (1995). "Carcinoembryonic antigen in staging and follow-up of patients ...
... evaluation of the leukocyte adherence inhibition test in colorectal cancer and its correlation with carcinoembryonic antigen ...
antigen processing and presentation of exogenous peptide antigen via MHC class II. • proteolysis. • neutrophil degranulation. ... brain antigen processing and regulation of programmed cell death.[17][18][19][20] ... Carcinoembryonic antigen. *CA 242. *Tumor-associated glycoprotein 72. Hepatocellular carcinoma. *Alpha-fetoprotein/AFP-L3 ...
Primarily, the VCAM-1 protein is an endothelial ligand for VLA-4 (Very Late Antigen-4 or integrin α4β1) of the β1 subfamily of ...
"Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients". Service of Internal Medicine, Hospital de ... "SEC" juga berfungsi sebagai sel presenter antigen yang menyediakan ekspresi MHC I dan MHC II bagi sel T. Sekresi yang terjadi ... Sel pit dapat menginduksi kematian seketika pada sel tumor tanpa bergantung pada ekspresi antigen pada kompleks ... dalam sistem kekebalan dengan banyaknya sel imunologis pada sistem retikuendotelial yang berfungsi sebagai tapis antigen yang ...
"Evaluation of the behavior of carcinoembryonic antigen in cirrhotic patients.". Service of Internal Medicine, Hospital de ... SEC uga duwé fungsi minangka sèl presenter antigen kang nyedhiakaké èksprèsi MHC I lan MHC II kanggo sèl T. Sèkrèsi kang dumadi ... Sèl pit bisa ngindhuksi pepati sanalika ing sèl tumor tanpa gumantung ing èksprèsi antigen ing komplèks histokompatibilitas ... sajeroning sistem kakebalan kanthi akèhé sèl imunologis ing sistem retikuendotelial kang duwé fungsi minangka tapis antigen ...
A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with ... By its nature, RIT requires a tumor cell to express an antigen that is unique to the neoplasm or is not accessible in normal ... The ability for the antibody to specifically bind to a tumor-associated antigen increases the dose delivered to the tumor cells ... an antibody with specificity for a tumor-associated antigen is used to deliver a lethal dose of radiation to the tumor cells. ...
Arcitumomab is a mouse antibody that recognizes Carcinoembryonic antigen, an antigen over-expressed in 95% of colorectal ... The antigen-binding fragment (Fab) is a region on an antibody that binds to antigens. It is composed of one constant and one ... Sulesomab, an antigen that recognizes proteins on the surface of granulocytes, is used to label out infections, again using the ... The variable domain contains the paratope (the antigen-binding site), comprising a set of complementarity determining regions, ...
2003). „Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin ...
Blood tests for tumor markers, such as carcinoembryonic antigen (CEA) and carbohydrate antigen (CA) may be ordered, as their ...
目前沒有特定的血液檢查方法能直接診斷出膽管癌。膽管癌患者血漿中的癌胚抗原(英语:carcinoembryonic antigen)和CA19-9(英语:CA19-9)濃度通常會提高,但其專一度和敏感度都不
... and carcinoembryonic antigen (CEA)). Rarely, spermatocytic seminomas may show sarcomatoid differentiation, most commonly as ...
Carcinoembryonic antigen. *CA 242. *Tumor-associated glycoprotein 72. Hepatocellular carcinoma. *Alpha-fetoprotein/AFP-L3 ...
"Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in ... In humans, the CD44 antigen is encoded by the CD44 gene on Chromosome 11.[5] CD44 has been referred to as HCAM (homing cell ... The CD44 antigen is a cell-surface glycoprotein involved in cell-cell interactions, cell adhesion and migration. ... Indian blood group system at BGMUT Blood Group Antigen Gene Mutation Database at NCBI, NIH ...
Another example is carcinoembryonic antigen, which is elevated in people with colon cancer and other tumors. Other oncofetal ... also known as oncofetal antigen protein). Oncofetal antigens are promising targets for vaccination against several types of ... Oncofetal antigens are proteins which are typically present only during fetal development but are found in adults with certain ... One example of an oncofetal antigen is alpha-fetoprotein, which is produced by hepatocellular carcinoma and some germ cell ...
... discovered Carcinoembryonic antigen Jules T. Freund (1890-1960) Sankar Ghosh John Grange Waldemar Haffkine (1860-1930), first ... isolation and partial characterization of A and B blood antigens Jian Zhou (1957-1999), with co-inventor Ian Frazer has ...
PRRs also mediate the initiation of antigen-specific adaptive immune response and release of inflammatory cytokines The microbe ... In addition, many of acquired nonself surfaces e.g. carcinoembryonic/oncofetal type neoantigens carrying "internal danger ... CLEC12B DC immunoreceptor (DCIR) subfamily which includes: DCIR/CLEC4A Dectin 2/CLEC6A Blood DC antigen 2 (BDCA2) ( CLEC4C) ... Tissue Antigens. 68 (3): 193-209. doi:10.1111/j.1399-0039.2006.00649.x. PMID 16948640. "Understanding Immunotherapy". Cancer. ...
... carcinoembryonic antigen - carrier - carrier protein - CAS registry number - casein - catabolism - catalyst - catalytic domain ... CCR5 receptor - CD4 antigen - CD45 antigen - CD95 antigen - CDC28 protein kinase - cell - cell adhesion molecule - Cell biology ... T-cell antigen receptors - tachykinin - tachykinin receptor - talin protein - tandem repeat sequence - taste bud - TATA box - ... alpha-beta T-cell antigen receptor - alpha-fetoprotein - alpha-globulin - alpha-macroglobulin - alpha-MSH - Ames test - amide ...
In 1968, he co-discovered with Samuel O. Freedman the carcinoembryonic antigen (CEA), which resulted in a blood test used in ...
... matrix metalloproteinases and tumour markers such as carcinoembryonic antigen. Pleural fluid mesothelin has a sensitivity of 71 ...
In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. The following is a ... Carcinoembryonic Antigen at the US National Library of Medicine Medical Subject Headings (MeSH) CEA at Lab Tests Online CEA: ... Carcinoembryonic antigen (CEA) describes a set of highly related glycoproteins involved in cell adhesion. CEA is normally ... Ballesta, AM; Molina, R; Filella, X; Jo, J; Giménez, N (1995). "Carcinoembryonic antigen in staging and follow-up of patients ...
... is an antigen (protein) present in very small quantities in adult tissue. A greater than normal amount may be suggestive of ... Carcinoembryonic antigen (CEA) is an antigen (protein) present in very small quantities in adult tissue. A greater than normal ... It is also referred to as an oncofetal antigen because of its similarity to fetal tissue. ... www.healthcentral.com/encyclopedia/carcinoembryonic-antigen. Encyclopedia /C /. Carcinoembryonic Antigen. Carcinoembryonic ...
CARCINOEMBRYONIC ANTIGEN. by Mena Report; Business, international Carcinoembryonic antigen CEA (Oncology) ... ANTIGEN.-a0313924654,/a,. Citations: *MLA style: "France - CARCINOEMBRYONIC ANTIGEN.." The Free Library. 2013 Al Bawaba (Middle ... ANTIGEN.-a0313924654. *Chicago style: The Free Library. S.v. France - CARCINOEMBRYONIC ANTIGEN.." Retrieved Dec 10 2017 from ... ANTIGEN.-a0313924654. *APA style: France - CARCINOEMBRYONIC ANTIGEN.. (n.d.) >The Free Library. (2014). Retrieved Dec 10 2017 ...
Alternate names for CEA include carcinoembryonic antigen-related cell adhesion molecule, CD66, meconium antigen, biliary ... Carcinoembryonic antigen (CEA) is a glycosylphosphatidylinositol (GPI)-cell surface anchored glycoprotein, first identified in ... Antigen/protein. Cat. #. Application. Species. (Clone) and Source. Cross‑Reactivity. CEA. 10094A, B, C. IHC. Human. (1B2). ... Does not cross‑react with CEA antisera such as nonspecific cross-reacting antigen (NCA) derived from lung and spleen, NCA-2 ...
A novel magnetic nanoparticle-based electrochemical immunoassay of carcinoembryonic antigen (CEA) was designed as a model using ... A Sandwich Electrochemical Immunosensor Using Magnetic DNA Nanoprobes for Carcinoembryonic Antigen. Ning Gan 1,†,* , Liyong Jia ... Keywords: chitosan/DNA/Fe3O4/ZrO2; magnetic nanoparticle-based electrochemical immunoassay; carcinoembryonic antigen; sandwich ... "A Sandwich Electrochemical Immunosensor Using Magnetic DNA Nanoprobes for Carcinoembryonic Antigen." Int. J. Mol. Sci. 12, no. ...
Keywords: carcinoembryonic antigen, pancreatic cancer, diagnosis, prognosis, meta-analysis ... Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%-60% of patients with ... Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and ... Diagnostic and prognostic value of carcinoembryonic antigen in pancreatic cancer: a systematic review and meta-analysis Qingcai ...
... carcinoembryonic antigen related cell adhesion molecule 6), Authors: Dessen P. Published in: Atlas Genet Cytogenet Oncol ... carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen). ...
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of ... Carcinoembryonic Antigen. Does this test have other names?. CEA. What is this test?. This test measures a protein called ... carcinoembryonic antigen (CEA) in your blood. This protein is found on some types of cancer cells. ...
A new study challenges the practice of measuring carcinoembryonic antigen (CEA) in patients with colon cancer prior to surgery ...
The Development of a Radioimmuno-Assay for Carcino-Embryonic Antigen with some Applications. Clinical Evaluation of Cercino- ...
Global carcinoembryonic antigen market value surpassed USD 1.9 billion in 2017 and is expected to witness more than 6.7% CAGR ... Carcinoembryonic Antigen (CEA) Market, By Gender Carcinoembryonic antigen market for males held the majority of the market ... Carcinoembryonic Antigen Industry Background. The global carcinoembryonic antigen market size is driven globally by innovation ... Carcinoembryonic Antigen Market Report Coverage. Report Coverage. Details. Base Year:. 2017. Market Size in 2017:. 1.9 Billion ...
Carcinoembryonic Antigen (CEA) / CD66 Antibody, Mouse Monoclonal Antibody [Clone SPM584 ] validated in WB, IHC, IF, FC (AH11034 ... Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen, CEA, Meconium antigen 100, CD66e, CEACAM5 ... home , Products , Primary Antibodies , Stem Cells , Carcinoembryonic Antigen (CEA) / CD66 Antibody Carcinoembryonic Antigen ( ... Carcinoembryonic Antigen (CEA) / CD66 Antibody is for research use only and not for use in diagnostic or therapeutic procedures ...
The Hepatic Uptake of the Non-Specific Cross-Reacting Antigen, a Glycoprotein related to Carcinoembryonic Antigen. PETER THOMAS ... The Hepatic Uptake of the Non-Specific Cross-Reacting Antigen, a Glycoprotein related to Carcinoembryonic Antigen ... The Hepatic Uptake of the Non-Specific Cross-Reacting Antigen, a Glycoprotein related to Carcinoembryonic Antigen ... The Hepatic Uptake of the Non-Specific Cross-Reacting Antigen, a Glycoprotein related to Carcinoembryonic Antigen ...
Carcinoembryonic Antigen (CEA) / CD66 Antibody - Without BSA and Azide, Mouse Monoclonal Antibody [Clone SPM551 ] validated in ... Carcinoembryonic antigen-related cell adhesion molecule 5, Carcinoembryonic antigen, CEA, Meconium antigen 100, CD66e, CEACAM5 ... Carcinoembryonic Antigen (CEA) / CD66 Antibody - Without BSA and Azide is for research use only and not for use in diagnostic ... home , Products , Primary Antibodies , Stem Cells , Carcinoembryonic Antigen (CEA) / CD66 Antibody - Without BSA and Azide ...
Definition of carcinoembryonic antigen. Provided by Stedmans medical dictionary and Drugs.com. Includes medical terms and ... carcinoembryonic antigen. Definition: a glycoprotein constituent of the glycocalyx of embryonic endodermal epithelium, which ...
... carcinoembryonic antigen (CEA), provides a suitable candidate for studying one such property related to a particular type of ... It has been proposed, however, that tumour-specific antigens such as CEA are not indigenous to the tumours, but are ... It therefore seems reasonable to expect that cell products such as tumour-associated antigens could, if present from the outset ... In vitro carcinoembryonic antigen production by human gastric carcinoma xenograft in nude mice *Ivy Benjamin ...
Carcinoembryonic antigen peptide-1 is a nine amino acid peptide fragment of carcinoembryonic antigen (CEA), a protein that is ... Synonyms: CAP-1 Carcinoembryonic Antigen Peptide-1 Carcinoembryonic Peptide-1 CEA Peptide 1 CEA Peptide 9-mer National Cancer ...
In this prospective study, we examined the usefulness of the carcinoembryonic antigen (CEA) and cytokeratin 20 (CK20) mRNA ... Prospective study of the quantitative carcinoembryonic antigen and cytokeratin 20 mRNA detection in peritoneal washes to ...
carcinoembryonic antigen-related cell adhesion molecule 1. Names. CD66a antigen. antigen CD66. carcinoembryonic antigen-related ... CEACAM1 carcinoembryonic antigen related cell adhesion molecule 1 [Homo sapiens] CEACAM1 carcinoembryonic antigen related cell ... carcinoembryonic antigen related cell adhesion molecule 1provided by HGNC. Primary source. HGNC:HGNC:1814 See related. Ensembl: ... CEACAM1 carcinoembryonic antigen related cell adhesion molecule 1 [ Homo sapiens (human) ] Gene ID: 634, updated on 19-Aug-2018 ...
Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma.. Goldenberg DM1, ... This prospective, multicenter study evaluated the accuracy, safety, and immunogenicity of carcinoembryonic antigen (CEA) ...
Goat polyclonal Carcino Embryonic Antigen CEA antibody validated for RIA and tested in Human. Immunogen corresponding to full ... Anti-Carcino Embryonic Antigen CEA antibody. See all Carcino Embryonic Antigen CEA primary antibodies. ...
Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines. R S Accolla, S Carrel, and J ... Spleen cells from mice immunized with purified carcinoembryonic antigen (CEA), an important tumor marker of human carcinomas, ... Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines ... Monoclonal antibodies specific for carcinoembryonic antigen and produced by two hybrid cell lines ...
Carcinoembryonic Antigen Levels in Benign and Malignant Pleural Effusions Annals of Internal Medicine; 88 (5): 631-634 ... The level of carcinoembryonic antigen (CEA) is often elevated in the serum of patients with cancer. This article reviews the ... Sequential Carcinoembryonic Antigen Levels in the Therapy of Metastatic Breast Cancer: A Predictor and Monitor of Response and ... Carcinoembryonic Antigen Elevation in Renal Failure Annals of Internal Medicine; 91 (6): 867-868 ...
Mouse monoclonal Carcino Embryonic Antigen CEA antibody [CB30] validated for ELISA, IHC and tested in Human. Referenced in 1 ... Anti-Carcino Embryonic Antigen CEA antibody [CB30] (FITC) (ab106739) *Anti-Carcino Embryonic Antigen CEA antibody [CB30] ( ... Anti-Carcino Embryonic Antigen CEA antibody [CB30]. See all Carcino Embryonic Antigen CEA primary antibodies. ...
... Test Overview. The carcinoembryonic antigen (CEA) test measures the amount of this protein that ... Carcinoembryonic antigenfootnote 1. Normal:. Less than 5 nanograms per milliliter (ng/mL) or less than 5 micrograms per liter ( ... The carcinoembryonic antigen (CEA) test measures the amount of this protein that may appear in the blood of some people who ... The carcinoembryonic antigen (CEA) test is used to monitor a person before and during treatment. Along with other tests, this ...
Role of Plasma Carcinoembryonic Antigen in Diagnosis of Gastrointestinal, Mammary, and Bronchial Carcinoma Br Med J 1972; 3 : ... Role of Plasma Carcinoembryonic Antigen in Diagnosis of Gastrointestinal, Mammary, and Bronchial Carcinoma. Br Med J 1972; 3 ... Our studies have confirmed that raised plasma levels of carcinoembryonic antigen (C.E.A.) occur with many but not all malignant ... Role of Plasma Carcinoembryonic Antigen in Diagnosis of Gastrointestinal, Mammary, and Bronchial Carcinoma ...
This test measures a protein called carcinoembryonic antigen (CEA) in your blood. This protein is present on some types of ... Carcinoembryonic Antigen. Does this test have other names?. CEA. What is this test?. This test measures a protein called ... carcinoembryonic antigen (CEA) in your blood. This protein is found on some types of cancer cells. ...
"Carcinoembryonic Antigen" by people in Harvard Catalyst Profiles by year, and whether "Carcinoembryonic Antigen" was a major or ... "Carcinoembryonic Antigen" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical ... Below are the most recent publications written about "Carcinoembryonic Antigen" by people in Profiles. ... Below are MeSH descriptors whose meaning is more general than "Carcinoembryonic Antigen". ...
Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters. By David M. Goldenberg, Hans J. ... Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters. By David M. Goldenberg, Hans J. ... Carcinoembryonic Antigen Present in Human Colonic Neoplasms Serially Propagated in Hamsters Message Subject. (Your Name) has ... Carcinoembryonic antigen, as measured by radioimmunoassay, is present in two different human colonic tumors that have been ...
... and carcinoembryonic antigen (CEA) are elevated in diabetic nephropathy (DN) and the association between urinary albumin-to- ... i,Objective,/i,. We aimed to explore whether squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (Cyfra21-1), neuron ... SCC: squamous cell carninoma antigen; Cyfra21-1: cytokeratin 19 fragment antigen 21-1; CEA: carcinoembryonic antigen. Model 1 ... SCC: squamous cell carninoma antigen; Cyfra21-1: cytokeratin 19 fragment antigen 21-1; CEA: carcinoembryonic antigen.. ...
Carcinoembryonic antigen-related cell adhesion molecule 1. Details. Name. Carcinoembryonic antigen-related cell adhesion ... Carcinoembryonic antigen-related cell adhesion molecule 1. P13688. Details. Drug Relations. Drug Relations. DrugBank ID. Name. ...
The carcinoembryonic antigen (CEA) is a human tumor marker whose gene belongs to a family with more than 20 members. This gene ... Characterization of Murine Carcinoembryonic Antigen Gene Family Members. In: Mammalian Genome, Vol. 3, No. 5: pp. 247-297 ...
Aluminum tetrasulfophthalocyanine (AlPcS4) was covalently coupled to a 35A7 MAb directed against carcinoembryonic antigen (CEA ... Aluminum tetrasulfophthalocyanine (AlPcS4) was covalently coupled to a 35A7 MAb directed against carcinoembryonic antigen (CEA ... Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine ...
Specificity and Affinity of Monoclonal Antibodies against Carcinoembryonic Antigen. Marius Nap, Marie-Louise Hammarström, Ole ... Specificity and Affinity of Monoclonal Antibodies against Carcinoembryonic Antigen. Marius Nap, Marie-Louise Hammarström, Ole ... Specificity and Affinity of Monoclonal Antibodies against Carcinoembryonic Antigen. Marius Nap, Marie-Louise Hammarström, Ole ... Specificity and Affinity of Monoclonal Antibodies against Carcinoembryonic Antigen Message Subject (Your Name) has forwarded a ...
Compare carcinoembryonic antigen related cell adhesion molecule 5 ELISA Kits from leading suppliers on Biocompare. View ... carcinoembryonic antigen related cell adhesion molecule 5 ELISA Kits. The ELISA (enzyme-linked immunosorbent assay) is a well- ... Your search returned 120 carcinoembryonic antigen related cell adhesion molecule 5 ELISA ELISA Kit across 18 suppliers. ... established antibody-based tool for detecting and quantifying antigens of interest. Ready-to-use ELISA Kits are available from ...
Carcinoembryonic antigen-related cell adhesion molecule 1 modulates vascular remodeling in vitro and in vivo. Andrea Kristina ... Angiogenic properties of the carcinoembryonic antigen-related cell adhesion molecule 1. Exp. Cell Res. 261:19-24. View this ... Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), a cellular adhesion molecule of the Ig superfamily, is ... Deletion of the carcinoembryonic antigen-related cell adhesion molecule 1 (Ceacam1) gene contributes to colon cancer ...
Carcinoembryonic Antigen Assay in Pleural Effusions N. C. THOMSON; B. RANA; J. G. RATCLIFFE ... Carcinoembryonic Antigen Assay in Pleural Effusions. Ann Intern Med. ;90:720-721. doi: 10.7326/0003-4819-90-4-720 ... To the editor: The role, if any, of the carcinoembryonic antigen (CEA) assay in differentiating malignant from benign pleural ...
Testing for carcino-embryonic antigen (CEA) in the blood is a recommended part of follow-up to detect recurrence of colorectal ... Detecting recurrent colorectal cancer by testing for blood carcino-embryonic antigen (CEA).. Background ... When this occurs, it usually causes a rise in a blood protein called CEA (carcino-embryonic antigen). An increased level of CEA ...
  • This antibody is designed for the specific localization of human carcinoembryonic antigen using IHC techniques in formalin-fixed, paraffin-embedded tissue sections. (gennovascientific.com)
  • Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized. (dovepress.com)
  • Serum tumour marker CEA ( Carcinoembryonic antigen ) is a glycoprotein of heterogeneous composition (MW 200000) normally detected in glycocalyx of fetal epithelial cells, mainly those of mucin secreting glandular nature. (thefreedictionary.com)
  • Based on the clinical observation that a significant proportion of patients with relapsing tumor show an elevated serum carcinoembryonic antigen (CEA) concentration while serum neuron-specific enolase (NSE) concentration remains normal, we attempted to determine whether the tissue expression of CEA is indicative of a clonal change in SCLC, in contrast with the tissue expression of NSE and P-glycoprotein (P-gp). (elsevier.com)
  • The present study examined serum tumor marker levels of carcinoembryonic antigen and cancer antigen 15-3 among patients with different subtypes of metastatic breast cancer.Methods: In this cross-sectional study, we assessed metastatic breast cancer patients diagnosed between 2005 and 2012 who referred to academic Hospitals affiliated with Mashhad University of Medical Sciences. (ac.ir)
  • Elevated serum levels of carcinoembryonic antigen were identified in 65.17% of patients and cancer antigen 15-3 in 57.29% of patients. (ac.ir)
  • There was no significant correlation between serum carcinoembryonic antigen and cancer antigen 15-3 with subtypes of the tumor. (ac.ir)
  • There was a significant association between serum carcinoembryonic antigen level and stages IIA and IV.Conclusion: One of the most significant findings of the current study was the increased serum carcinoembryonic antigen and cancer antigen 15-3 levels in most metastatic breast cancer participants. (ac.ir)
  • We postulate that regular measurement of serum cancer antigen 15-3 and carcinoembryonic antigen could be useful for earlier detection and prediction of outcomes. (ac.ir)
  • Assessment of Elevated Serum Tumor Markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3) among Patients with Different Subtypes of Metastatic Breast Cancer', Middle East Journal of Cancer , 10(1), pp. 17-22. (ac.ir)
  • General information: Carcinoembryonic antigen (CEA) is a glycoprotein found in the fetal gastrointestinal tract during the first six months of gestation. (thefreelibrary.com)
  • Carcino embroyonic antigen (CEA) is a cell-surface 200-kd glycoprotein. (cd-diatest.com)
  • The carcinoembryonic antigen gene family consists of the CEA- and the Pregnancy-Specific Glycoprotein- (PSG) subfamilies. (elsevier.com)
  • Khan, WN & Hammarström, S 1990, ' Identification of a new carcinoembryonic antigen (CEA) family member in human fetal liver - Cloning and sequence determination of pregnancy- specific glycoprotein 7 ', Biochemical and biophysical research communications , vol. 168, no. 1, pp. 214-225. (elsevier.com)
  • Carcinoembryonic Antigen Market size was valued over USD 1.9 billion in 2017 and is expected to witness more than 6.7% CAGR from 2018 to 2024. (gminsights.com)
  • Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful? (wikipedia.org)
  • Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting," British Journal of Cancer, vol. (thefreedictionary.com)
  • The ASL-32 mAb reacts with an antigen epitope shared by CD66a, c and e. (biolegend.com)
  • Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. (ac.ir)
  • Previous studies have noted conflicting results about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic breast cancer. (ac.ir)
  • It seems to be a good time to take a broader look at T cell manipulation, especially as it pertains to the application of TILs, chimeric antigen receptors (CAR), and T cell receptors (TCR). (biotechstrategyblog.com)
  • Carcinoembryonic antigen (CEA), is synthesized during development in the fetal gut, and is re-expressed in increased amounts in intestinal carcinomas and several other tumors. (gennovascientific.com)
  • We have previously demonstrated the existence of a novel inhibitory mechanism of NK cell cytotoxicity mediated by the homophilic carcinoembryonic Ag (CEA)-related cell adhesion molecule 1 (CEACAM1) interactions. (ox.ac.uk)
  • Carcinoembryonic antigen is the recurrent indicator in asymptomatic patients and presently the most cost-effective assessment for preclinical detection of illness. (gminsights.com)
  • However, ineffective approach for cancer detection at initial stage and lack of awareness are restraining the carcinoembryonic antigen market growth. (gminsights.com)
  • Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%-60% of patients with pancreatic cancer. (dovepress.com)
  • Pancreatic cancer exhibits a number of tumor-specific antigens, such as carcinoembryonic antigen , mesothelin, HER-2, and MUC1, which are promising applicants for testing CARs T-cell therapy [55,56]. (thefreedictionary.com)
  • It is also referred to as an 'oncofetal antigen' because of its similarity to fetal tissue. (healthcentral.com)
  • CD66a (BGP), an adhesion molecule of the carcinoembryonic antigen family, is expressed in epithelium, endothelium, and myeloid cells in a wide range of normal human tissues," Journal of Histochemistry & Cytochemistry, vol. (thefreedictionary.com)
  • Freedman, S. O. : Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. (acris-antibodies.com)
  • In humans, the carcinoembryonic antigen family consists of 29 genes, 18 of which are normally expressed. (wikipedia.org)
  • Carcinoembryonic Antigen Market Size By Application (Gastrointestinal Cancer [Colon Cancer, Pancreat. (gminsights.com)
  • This paper revisits the potential role of serum carcinoembryonic antigen (CEA) in follow-up. (mdpi.com)
  • This study aimed to clarify the clinical associations between serum carcinoembryonic antigen (CEA) levels and whole-body metastatic distribution in stage IV NSCLC patients. (jcancer.org)
  • Serum carcinoembryonic antigen (CEA) is an established and long-term tumor marker, which has demonstrated its prognostic value in colorectal neoplasms [ 5 , 6 ]. (jcancer.org)
  • Electrochemical immunoassay of carcinoembryonic antigen based on TiO2-graphene / thionine / gold nanoparticles composite. (ebscohost.com)
  • Enzyme-linked immunosorbent assay (ELISA) was used for analysis of serum mutant p53 protein and epidermal growth factor receptor (EGFR) and electrochem-iluminescence immunoassay (ECLIA) was used for analysis of carcinoembryonic antigen (CEA). (scopemed.org)
  • Sensitive label-free immunoassay of carcinoembryonic antigen based on Au-TiO2 hybrid nanocomposite film. (semanticscholar.org)
  • Global Markets Direct's, 'Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) - Pipeline Review, H1 2016', provides in depth analysis on Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted pipeline therapeutics. (reportsnreports.com)
  • The report provides comprehensive information on the Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. (reportsnreports.com)
  • Additionally, the report provides an overview of key players involved in Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5 (Carcinoembryonic Antigen or CEA or Meconium Antigen 100 or CD66e or CEACAM5) targeted therapeutics development and features dormant and discontinued projects. (reportsnreports.com)
  • The carcinoembryonic antigen (CEA)-related cell adhesion molecules CEACAM1 (BGP, CD66a), CEACAM5 (CEA, CD66e) and CEACAM6 (NCA, CD66c) are expressed in human lung. (biomedcentral.com)
  • An immunosensor has been fabricated for direct amperometric determination of carcinoembryonic antigen. (ebscohost.com)
  • Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful? (wikipedia.org)
  • The discovery by Gold and Freedman 2 of an antigenic substance specific for entodermally-derived cancers of the digestive system, carcinoembryonic antigen (CEA), provides a suitable candidate for studying one such property related to a particular type of human cancer. (nature.com)
  • Carcinoembryonic antigen peptide-1 is a nine amino acid peptide fragment of carcinoembryonic antigen (CEA), a protein that is overexpressed in several cancer cell types, including gastrointestinal, breast, and non-small cell lung. (wikipedia.org)
  • Up-regulation of carcinoembryonic antigen-related cell adhesion molecule 1 in gastrointestinal cancer and its clinical relevance. (nih.gov)
  • The level of carcinoembryonic antigen (CEA) is often elevated in the serum of patients with cancer. (annals.org)
  • Similarly, the antigen level cannot, by itself, provide enough diagnostic certainty to confirm or rule out suspected cancer. (annals.org)
  • The carcinoembryonic antigen (CEA) test measures the amount of this protein that may appear in the blood of some people who have certain kinds of cancers, especially cancer of the large intestine ( colon and rectal cancer ). (lmh.org)
  • Carcinoembryonic antigen (CEA) is one of the most widely used tumor markers and is increased in 30%-60% of patients with pancreatic cancer. (dovepress.com)
  • Although carbohydrate antigen 19-9 (CA19-9) is the most important serum biomarker in pancreatic cancer, the diagnostic and prognostic value of CEA is gradually being recognized. (dovepress.com)
  • Detecting recurrent colorectal cancer by testing for blood carcino-embryonic antigen (CEA). (cochrane.org)
  • Testing for carcino-embryonic antigen (CEA) in the blood is a recommended part of follow-up to detect recurrence of colorectal cancer following primary curative treatment. (cochrane.org)
  • Colorectal cancer application segment generated major revenue share of over 40% in the carcinoembryonic antigen market, and is estimated to exceed USD 1 billion by 2023. (gminsights.com)
  • North America led by U.S. carcinoembryonic antigen market accounted for over 75% revenue share in 2015, due to high patient awareness levels, high incidence rates of cancer and existence of sophisticated healthcare infrastructure in the region. (gminsights.com)
  • Carcinoembryonic antigen (CEA) is a tumor marker in the blood or other bodily fluids that can be used to monitor certain cancers such as colorectal cancer. (verywellhealth.com)
  • Carcinoembryonic antigen (CEA) is not used as a screening test for cancer for the general population but may be considered for people with some hereditary colorectal cancer syndromes. (verywellhealth.com)
  • We analyzed the ability of a recombinant replication-defective adenovirus vector with the carcinoembryonic antigen (CEA) promoter to transfer the thymidine kinase gene of herpes simplex virus ( HSVtk ) into gastric cancer cells to confer sensitivity to ganciclovir (GCV). (aacrjournals.org)
  • Our results suggest that early aberrant events induced in the immunoregulatory network by tumor-associated antigens may be relevant and may lead to better understanding of immunosuppression in the cancer-bearing host. (jimmunol.org)
  • Preoperative carcinoembryonic antigen (CEA) has yet to be used as a prognostic or adjuvant chemotherapy factor for colorectal cancer (CRC). (springer.com)
  • Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. (springer.com)
  • Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. (springer.com)
  • The prognostic significance of preoperative carcinoembryonic antigen levels in colorectal cancer. (springer.com)
  • We examined 202 lymph nodes obtained from 13 colorectal cancer patients who underwent curative operation and were histologically diagnosed to be node-negative, using RT-PCR to amplify mRNAs for two epithelial markers, carcinoembryonic antigen (CEA) and cytokeratin 20 (CK-20). (nih.gov)
  • We explored and validated the association of postoperative carcinoembryonic antigen (CEA) with disease-free survival (DFS) and overall survival (OS) in stage III colon cancer. (aacrjournals.org)
  • Carcinoembryonic Antigen Market Size By Application (Gastrointestinal Cancer [Colon Cancer, Pancreat. (gminsights.com)
  • However, ineffective approach for cancer detection at initial stage and lack of awareness are restraining the carcinoembryonic antigen market growth. (gminsights.com)
  • Leucocyte migration inhibition test (LMIT) is a useful method to detect tumor associated antigens (TAA) in cancer patients. (springer.com)
  • Carcinoembryonic antigen (CEA) is one of the best tumor markers for gastrointestinal cancer, and especially for colorectal cancer patients, who show high plasma CEA level frequently. (springer.com)
  • The results suggest that some antigens which induce leucocyte migration inhibition factor ( LMIF ) to lymphocytes from colorectal cancer patients might be different substances from CEA. (springer.com)
  • Previous studies have indicated that plasma concentrations of chromogranin A (CGA), cytokeratin 19 fragments (CYFRA 21-1), cancer antigen 125 (CA 125), cancer antigen 19-9 (CA 19-9) and carcinoembryonic antigen (CEA) are higher in patients with CKD but without cancer, than in healthy individuals, and this can make interpretation of results more complicated. (bibsys.no)
  • This prospective study in Yazd, Islamic Republic of Iran, assessed the value of the tumour markers carcinoembryonic antigen (CEA) and cancer antigen (CA) 15-3 in 159 patients with primary breast cancer. (who.int)
  • Carcinoembryonic antigen has a different molecular weight in normal colon and in cancer cells due to N-glycosylation differences. (springer.com)
  • Pancreatic cancer exhibits a number of tumor-specific antigens, such as carcinoembryonic antigen , mesothelin, HER-2, and MUC1, which are promising applicants for testing CARs T-cell therapy [55,56]. (thefreedictionary.com)
  • Carcinoembryonic antigen is the preferred biomarker for in vivo colorectal cancer targeting," British Journal of Cancer, vol. (thefreedictionary.com)
  • Clinically relevant values for progressive cancer antigen 15.3 and carcinoembryonic antigen concentrations were combined with representative values for background variations in a computer simulation model. (aaccjnls.org)
  • The potential roles of the serological tumor markers cancer antigen 15.3 (CA 15.3) 1 and carcinoembryonic antigen (CEA) in monitoring patients with metastatic breast cancer have been the subject of several studies ( 1 )( 2 )( 3 ). (aaccjnls.org)
  • The global carcinoembryonic antigen (CEA) market is segmented on the basis of application type into ovarian cancer, colorectal cancer, pancreatic cancer, lung cancer, breast cancer, thyroid cancer and other cancers. (mobilecomputingtoday.co.uk)
  • Carcinoembryonic antigen (CEA) is an antigen (protein) present in very small quantities in adult tissue. (healthcentral.com)
  • Carcinoembryonic antigen (CEA) is a protein normally found in very low levels in the blood of adults. (cancer.ca)
  • This test measures a protein called carcinoembryonic antigen (CEA) in your blood. (ahealthyme.com)
  • Reasons for this phenomenon are that tumor-associated antigens represent well-tolerated self-molecules of low antigenicity per se due to a high content of non-protein compounds including carbohydrates. (aacrjournals.org)
  • In a multi-purpose research program to provide a reliable source for large production of CEA, we converted the membrane-bound carcinoembryonic antigen into a secretory protein by site-specific mutagenesis. (springer.com)
  • Individual Neisseria gonorrhoeae colony opacity-associated (Opa) protein variants can bind up to four different carcinoembryonic antigen-related cellular adhesion molecule (CEACAM) receptors. (asm.org)
  • We have been developing a mouse model for this large protein family and have cloned a complementary DNA (cDNA) for a mouse carcinoembryonic antigen gene family member (mmCGM1a). (aacrjournals.org)
  • This gene encodes a member of the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily. (nih.gov)
  • The carcinoembryonic antigen (CEA) is a human tumor marker whose gene belongs to a family with more than 20 members. (uni-muenchen.de)
  • A long-range physical map of the carcinoembryonic antigen (CEA) gene family cluster, which is located on the long arm of chromosome 19, has been constructed. (uni-muenchen.de)
  • Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. (springer.com)
  • mmCGM1a: a mouse carcinoembryonic antigen gene family member, generated by alternative splicing, functions as an adhesion molecule -- McCuaig et al. (aacrjournals.org)
  • CEACAM-1 (BGP-1 or CD66a) belongs to the carcinoembryonic antigen (CEA) gene family. (neuromics.com)
  • Characterization of an immunosuppressive factor from malignant ascites that resembles a factor induced in vitro by carcinoembryonic antigen. (jimmunol.org)
  • This concept has been difficult to study until recently when carcinoembryonic antigen was shown to induce the release of such molecules from normal circulating human mononuclear cells in vitro. (jimmunol.org)
  • Similarities in m.w. (50,000 daltons), isoelectric point (pI = 3.4), physical properties (heat and acid stability and resistance to proteases), and immunologic activity of this factor with that released from lymphocytes after in vitro exposure to carcinoembryonic antigen indicates they may be identical. (jimmunol.org)
  • Your search returned 120 carcinoembryonic antigen related cell adhesion molecule 5 ELISA ELISA Kit across 18 suppliers. (biocompare.com)
  • MBS7211769 is a ready-to-use microwell, strip plate ELISA (enzyme-linked immunosorbent assay) Kit for analyzing the presence of the Carcinoembryonic antigen-related cell adhesion molecule 18 (CEACAM18) ELISA Kit target analytes in biological samples. (mybiosource.com)
  • The Development of a Radioimmuno-Assay for Carcino-Embryonic Antigen with some Applications. (hu-berlin.de)
  • Carcinoembryonic antigen immunoscintigraphy complements mammography in the diagnosis of breast carcinoma. (nih.gov)
  • For some cancers, antigen levels at the time of diagnosis provide more precise prognosis than staging alone, but this information does not lead to more effective treatment. (annals.org)
  • The four prominent constituents of the intestinal glycocalyx, carcinoembryonic antigen (CEA), CEA cell adhesion molecule 1 (CEACAM1), CEACAM6 and CEACAM7 all seem to play a critical role in innate defence of the intestinal mucosa by trapping and expelling microorganisms at the epithelial surface. (diva-portal.org)
  • To the editor: The role, if any, of the carcinoembryonic antigen (CEA) assay in differentiating malignant from benign pleural effusions is not yet clear, despite several recent reports on the subject (1-4). (annals.org)
  • It therefore seems reasonable to expect that cell products such as tumour-associated antigens could, if present from the outset, be retained in a demonstrable state when the tumour cells are cultivated outside the original host organism. (nature.com)
  • It has been proposed, however, that tumour-specific antigens such as CEA are not indigenous to the tumours, but are glycoproteins produced elsewhere in the body and coating the tumour cells secondarily 3 . (nature.com)
  • Our studies have confirmed that raised plasma levels of carcinoembryonic antigen (C.E.A.) occur with many but not all malignant tumours, particularly those of the gastrointestinal tract, breast, and bronchus. (bmj.com)
  • Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. (springer.com)
  • A pleural fluid carcinoembryonic antigen (CEA) concentration of 3.5 ng/mL or higher is suspicious but not diagnostic of a malignant source of the effusion. (mayocliniclabs.com)
  • Here, we generate a bispecific 4-1BB-agonistic trimerbody targeting the carcinoembryonic antigen (CEA) that is highly expressed in cancers of diverse origins. (frontiersin.org)
  • The antagonistic mAbs used in immune checkpoint blockade are able to block T cell-inhibitory signaling from receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1), and have been successfully used in the treatment of several types of cancers ( 1 ). (frontiersin.org)
  • The engagement of 4-1BB by its ligand or agonistic mAbs provides substantial boosts to the T cell response ( 4 ), which prompted the incorporation of 4-1BB intracellular signaling domain into TCR-like chimeric antigen receptors (CARs) and ultimately greatly improved their functionality ( 5 ). (frontiersin.org)
  • Matzku S, Zöller M, Schulz U, Deltze W, Barth HO, Saeger HD, Price MR: Lack of correlation between carcinoembryonic antigen content of tumor extracts and leucocyte migration reactivity of tumor patients. (springer.com)
  • We aimed to explore whether squamous cell carcinoma antigen (SCC), cytokeratin 19 fragment (Cyfra21-1), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA) are elevated in diabetic nephropathy (DN) and the association between urinary albumin-to-creatinine ratio (UACR) and tumor markers in diabetic patients. (hindawi.com)
  • and (2) the use of pretreatment and serial carcinoembryonic antigen (CEA) levels in these patients. (elsevier.com)